<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VIREAD - tenofovir disoproxil fumarate tablet, coated </strong><br>State of Florida DOH Central Pharmacy<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VIREAD safely and effectively. See full prescribing information for VIREAD.<br>VIREAD (tenofovir disoproxil fumarate) tablet, coated for oral use<br>Initial U.S. Approval: 2001</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported in HBV-infected patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including VIREAD.  Hepatic function should be monitored closely in these patients.  If appropriate, resumption of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="75%">
<col align="left" valign="bottom" width="70%">
<col align="right" valign="bottom" width="30%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Boxed Warning</td>
<td align="right">8/2008, 11/2008</td>
</tr>
<tr>
<td align="left">Indications and Usage (<a href="#S1.2">1.2</a>)</td>
<td align="right">8/2008</td>
</tr>
<tr>
<td align="left">Dosage and Administration (<a href="#S2.1">2.1</a>)</td>
<td align="right">8/2008</td>
</tr>
<tr>
<td align="left">Warnings and Precautions </td>
<td align="right"></td>
</tr>
<tr>
<td align="left">  Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> after Discontinuation  of Treatment (<a href="#S5.2">5.2</a>)</td>
<td align="right">8/2008</td>
</tr>
<tr>
<td align="left">  Decreases in Bone Mineral Density (<a href="#S5.6">5.6</a>)</td>
<td align="right">11/2008</td>
</tr>
<tr class="Botrule Last">
<td align="left">  Early Virologic Failure (<a href="#S5.9">5.9</a>)</td>
<td align="right">11/2008</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNINGS: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<ul>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD. (<a href="#S5.1">5.1</a>)</span></li>
<li><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported in HBV-infected patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including VIREAD.  Hepatic function should be monitored closely in these patients.  If appropriate, resumption of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#S5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">VIREAD is a nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor.  </p>
<p class="Highlighta">Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults. (<a href="#S1">1</a>) </p>
<p class="Highlighta">Viread is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in adults. (<a href="#S1">1</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Recommended dose for the treatment of HIV or <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B: 300 mg once daily taken orally without regard to food.  (<a href="#S2.1">2.1</a>)</li>
<li>Dose recommended in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>:<br>Creatinine clearance 30–49 mL/min: 300 mg every 48 hours. (<a href="#S2.2">2.2</a>)<br>Creatinine clearance 10–29 mL/min: 300 mg every 72 to 96 hours. (<a href="#S2.2">2.2</a>)<br>Hemodialysis: 300 mg every 7 days or after approximately 12 hours of dialysis. (<a href="#S2.2">2.2</a>)</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 300 mg. (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  (<a href="#S4">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>New onset or worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>: Can include <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>. Assess creatinine clearance (CrCl) before initiating treatment with VIREAD. Monitor CrCl and serum phosphorus in patients at risk. Avoid administering VIREAD with concurrent or recent use of nephrotoxic drugs, including HEPSERA. (<a href="#S5.3">5.3</a>)</li>
<li>Products with same active ingredient: Do not use with other tenofovir-containing products (e.g., ATRIPLA and TRUVADA). (<a href="#S5.4">5.4</a>)</li>
<li>HIV testing: HIV antibody testing should be offered to all HBV-infected patients before initiating therapy with VIREAD. VIREAD should only be used as part of an appropriate antiretroviral combination regimen in HIV-infected patients with or without HBV coinfection. (<a href="#S5.5">5.5</a>)</li>
<li>Decreases in bone mineral density (BMD): Observed in HIV-infected patients.  Consider monitoring BMD in patients with a history of pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or who are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>.  (<a href="#S5.6">5.6</a>)</li>
<li>Redistribution/accumulation of body fat: Observed in HIV-infected patients receiving antiretroviral combination therapy.  (<a href="#S5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span>: Observed in HIV-infected patients.  May necessitate further evaluation and treatment.  (<a href="#S5.8">5.8</a>)</li>
<li>Triple nucleoside-only regimens: Early virologic failure has been reported in HIV-infected patients. Monitor carefully and consider treatment modification. (<a href="#S5.9">5.9</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">In HIV-infected patients: Most common adverse reactions (incidence ≥10%, Grades 2 – 4) are <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (<a href="#S6">6</a>)  </p>
<p class="Highlighta">In HBV-infected patients: Most common adverse reaction (all grades) was <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (9%). (<a href="#S6">6</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Gilead Sciences, Inc. at 1-800-GILEAD-5 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul>
<li>Didanosine: Coadministration increases didanosine concentrations. Use with caution and monitor for evidence of didanosine toxicity (e.g., <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>). Consider dose reductions or discontinuations of didanosine if warranted. (<a href="#S7.1">7.1</a>)</li>
<li>Atazanavir: Coadministration decreases atazanavir concentrations and increases tenofovir concentrations. Use atazanavir with VIREAD only with additional ritonavir; monitor for evidence of tenofovir toxicity. (<a href="#S7.2">7.2</a>)</li>
<li>Lopinavir/ritonavir: Coadministration increases tenofovir concentrations. Monitor for evidence of tenofovir toxicity. (<a href="#S7.3">7.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Pregnancy: Pregnancy registry available. Enroll patients by calling 1-800-258-4263.</li>
<li>Nursing mothers: Women infected with HIV should be instructed not to breast feed. (<a href="#S8.3">8.3</a>)</li>
<li>Safety and efficacy not established in patients less than 18 years of age. (<a href="#S8.4">8.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 4/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNINGS:  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> </span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	<span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Dose Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> after Discontinuation of Treatment</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Coadministration with Other Products</a></h2>
<h2><a href="#section-5.5" class="toc">5.5       Patients Coinfected with HIV-1 and HBV</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Decreases in Bone Mineral Density</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Fat Redistribution</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9	Early Virologic Failure</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Adverse Reactions from Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc"></a></h2>
<h2><a href="#section-6.3" class="toc"></a></h2>
<h2><a href="#section-6.4" class="toc"></a></h2>
<h2><a href="#section-6.5" class="toc"></a></h2>
<h2><a href="#section-6.6" class="toc"></a></h2>
<h2><a href="#section-6.7" class="toc"></a></h2>
<h2><a href="#section-6.8" class="toc"></a></h2>
<h2><a href="#section-6.9" class="toc"></a></h2>
<h2><a href="#section-6.10" class="toc"></a></h2>
<h2><a href="#section-6.11" class="toc"></a></h2>
<h2><a href="#section-6.12" class="toc"></a></h2>
<h2><a href="#section-6.13" class="toc"></a></h2>
<h2><a href="#section-6.14" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Didanosine</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	Atazanavir </a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Lopinavir/Ritonavir</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Drugs Affecting Renal Function</a></h2>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.2" class="toc"></a></h2>
<h2><a href="#section-8.3" class="toc"></a></h2>
<h2><a href="#section-8.4" class="toc">8.3	Nursing Mothers</a></h2>
<h2><a href="#section-8.5" class="toc">8.4	Pediatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.5	Geriatric Use</a></h2>
<h2><a href="#section-8.7" class="toc">8.6	Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3	Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc"></a></h2>
<h2><a href="#section-11.4" class="toc"></a></h2>
<h2><a href="#section-11.5" class="toc"></a></h2>
<h2><a href="#section-11.6" class="toc"></a></h2>
<h2><a href="#section-11.7" class="toc"></a></h2>
<h2><a href="#section-11.8" class="toc"></a></h2>
<h2><a href="#section-11.9" class="toc"></a></h2>
<h2><a href="#section-11.10" class="toc"></a></h2>
<h2><a href="#section-11.11" class="toc"></a></h2>
<h2><a href="#section-11.12" class="toc"></a></h2>
<h2><a href="#section-11.13" class="toc"></a></h2>
<h2><a href="#section-11.15" class="toc"></a></h2>
<h2><a href="#section-11.16" class="toc"></a></h2>
<h2><a href="#section-11.17" class="toc"></a></h2>
<h2><a href="#section-11.18" class="toc"></a></h2>
<h2><a href="#section-11.19" class="toc"></a></h2>
<h2><a href="#section-11.20" class="toc"></a></h2>
<h2><a href="#section-11.21" class="toc"></a></h2>
<h2><a href="#section-11.22" class="toc"></a></h2>
<h2><a href="#section-11.23" class="toc"></a></h2>
<h2><a href="#section-11.24" class="toc"></a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2	Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.2" class="toc"></a></h2>
<h2><a href="#section-13.3" class="toc"></a></h2>
<h2><a href="#section-13.4" class="toc"></a></h2>
<h2><a href="#section-13.5" class="toc"></a></h2>
<h2><a href="#section-13.6" class="toc"></a></h2>
<h2><a href="#section-13.8" class="toc"></a></h2>
<h2><a href="#section-13.9" class="toc"></a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc"></a></h2>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="Box"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNINGS:  <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span>/SEVERE <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span> WITH STEATOSIS and POST TREATMENT EXACERBATION OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> </span></h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD, in combination with other antiretrovirals  <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported in HBV-infected patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including VIREAD.  Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including VIREAD.  If appropriate, resumption of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted  <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
<p class="First">VIREAD<span class="Sup">®</span> is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>The following points should be considered when initiating therapy with VIREAD for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</p>
<ul><li>VIREAD should not be used in combination with TRUVADA<span class="Sup">®</span> or ATRIPLA<span class="Sup">®</span> [<span class="Italics">See <a href="#S5.4">Warnings and Precautions (5.4)</a></span>].</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	<span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">VIREAD is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B in adults.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The following points should be considered when initiating therapy with VIREAD for the treatment of HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</span></p>
<ul>
<li style="border-left:1px solid;"><span class="XmChange">This indication is based on data from one year of treatment in primarily nucleoside-treatment-naïve adult patients with HBeAg-positive and HBeAg-negative <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B with compensated liver disease <span class="Italics">[See <a href="#S14.2">Clinical Efficacy in Patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B (14.2)</a>]</span>.</span></li>
<li style="border-left:1px solid;"><span class="XmChange">The numbers of patients in clinical trials who were nucleoside-experienced or who had lamivudine-associated mutations at baseline were too small to reach conclusions of efficacy <span class="Italics">[See <a href="#S14.2">Clinical Efficacy in Patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B (14.2)</a>].</span></span></li>
<li style="border-left:1px solid;"><span class="XmChange">VIREAD has not been evaluated in patients with decompensated liver disease.</span></li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Recommended Dose</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">For the treatment of HIV-1 or <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B: The dose of VIREAD is 300 mg once daily taken orally, without regard to food.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">In the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, the optimal duration of treatment is unknown.  </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Dose Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Significantly increased drug exposures occurred when VIREAD was administered to patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Therefore, the dosing interval of VIREAD should be adjusted in patients with baseline creatinine clearance &lt;50 mL/min using the recommendations in Table 1. These dosing interval recommendations are based on modeling of single-dose pharmacokinetic data in non-HIV and non-HBV infected subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring hemodialysis. The safety and effectiveness of these dosing interval adjustment recommendations have not been clinically evaluated in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, therefore clinical response to treatment and renal function should be closely monitored in these patients <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<p>No dose adjustment is necessary for patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 50–80 mL/min). Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients with mild <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1 Dosage Adjustment for Patients with Altered Creatinine Clearance</span></caption>
<col align="left" valign="middle" width="33%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="11%">
<col align="center" valign="bottom" width="34%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="3">Creatinine Clearance<br> (mL/min)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center"></th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">≥50</th>
<th class="Rrule" align="center">30–49</th>
<th class="Rrule" align="center">10–29</th>
<th class="Rrule" align="center">Hemodialysis Patients</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Calculated using ideal (lean) body weight.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Generally once weekly assuming three hemodialysis sessions a week of approximately 4 hours duration. VIREAD should be administered following completion of dialysis.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Lrule Rrule" align="left"><span class="Bold">Recommended 300 mg Dosing Interval</span></td>
<td class="Rrule" align="center">Every 24 hours</td>
<td class="Rrule" align="center">Every 48 hours</td>
<td class="Rrule" align="center">Every 72 to 96 hours</td>
<td class="Rrule" align="center">Every 7 days or after a total of approximately 12 hours of dialysis<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</td>
</tr></tbody>
</table>
<p>The pharmacokinetics of tenofovir have not been evaluated in non-hemodialysis patients with creatinine clearance &lt;10 mL/min; therefore, no dosing recommendation is available for these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">VIREAD is available as tablets. Each tablet contains 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. The tablets are almond-shaped, light blue, film-coated, and debossed with "GILEAD" and "4331" on one side and with "300" on the other side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<p class="First">None. </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including VIREAD,  in combination with other antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogs to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. Treatment with VIREAD should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> after Discontinuation of Treatment</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Discontinuation of anti-HBV therapy, including VIREAD, may be associated with severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.  Patients infected with HBV who discontinue VIREAD should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.  If appropriate, resumption of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Tenofovir is principally eliminated by the kidney. <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span> (renal tubular injury with severe <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>), has been reported with the use of VIREAD <span class="Italics">[See <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</p>
<p>It is recommended that creatinine clearance be calculated in all patients prior to initiating therapy and as clinically appropriate during therapy with VIREAD. Routine monitoring of calculated creatinine clearance and serum phosphorus should be performed in patients at risk for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Dosing interval adjustment of VIREAD and close monitoring of renal function are recommended in all patients with creatinine clearance &lt;50 mL/min <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>. No safety or efficacy data are available in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who received VIREAD using these dosing guidelines, so the potential benefit of VIREAD therapy should be assessed against the potential risk of renal toxicity.</p>
<p>VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Coadministration with Other Products</h2>
<p class="First">VIREAD should not be used in combination with the fixed-dose combination products TRUVADA or ATRIPLA since tenofovir disoproxil fumarate is a component of these products.</p>
<p>VIREAD should not be administered in combination with HEPSERA<span class="Sup">®</span> (adefovir dipivoxil) <span class="Italics">[See <a href="#S7.4">Drug Interactions (7.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5       Patients Coinfected with HIV-1 and HBV</h2>
<p class="First">Due to the risk of development of HIV-1 resistance, VIREAD should only be used in HIV-1 and HBV coinfected patients as part of an appropriate antiretroviral combination regimen.</p>
<p>HIV-1 antibody testing should be offered to all HBV-infected patients before initiating therapy with VIREAD.  It is also recommended that all patients with HIV-1 be tested for the presence of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B before initiating treatment with VIREAD.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Decreases in Bone Mineral Density</h2>
<p class="First">Bone mineral density (BMD) monitoring should be considered for patients who have a history of pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or are at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>.  Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients.  If bone abnormalities are suspected then appropriate consultation should be obtained.</p>
<p>In HIV-infected patients treated with VIREAD in Study 903 through 144 weeks, decreases from baseline in BMD were seen at the lumbar spine and hip in both arms of the study. At Week 144, there was a significantly greater mean percentage decrease from baseline in BMD at the lumbar spine in patients receiving VIREAD + lamivudine + efavirenz (-2.2% ± 3.9) compared with patients receiving stavudine + lamivudine + efavirenz (-1.0% ± 4.6). Changes in BMD at the hip were similar between the two treatment groups (-2.8% ± 3.5 in the VIREAD group vs. -2.4% ± 4.5 in the stavudine group). In both groups, the majority of the reduction in BMD occurred in the first 24–48 weeks of the study and this reduction was sustained through Week 144. Twenty-eight percent of VIREAD-treated patients vs. 21% of the stavudine-treated patients lost at least 5% of BMD at the spine or 7% of BMD at the hip. Clinically relevant <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> (excluding fingers and toes) were reported in 4 patients in the VIREAD group and 6 patients in the stavudine group. In addition, there were significant increases in biochemical markers of bone metabolism (serum bone-specific alkaline phosphatase, serum osteocalcin, serum C-telopeptide, and urinary N-telopeptide) in the VIREAD group relative to the stavudine group, suggesting increased bone turnover. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher in the VIREAD group. Except for bone specific alkaline phosphatase, these changes resulted in values that remained within the normal range. The effects of VIREAD-associated changes in BMD and biochemical markers on long-term bone health and future <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> risk are unknown.</p>
<p style="border-left:1px solid;"><span class="XmChange">Cases of <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (associated with proximal renal tubulopathy and which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) have been reported in association with the use of VIREAD <span class="Italics">[See <a href="#S6.2">Adverse Reactions (6.2)</a>]</span>.</span></p>
<p>The bone effects of VIREAD have not been studied in patients with chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Fat Redistribution</h2>
<p class="First">In HIV-infected patients redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and "<span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> appearance" have been observed in patients receiving combination antiretroviral therapy.  The mechanism and long-term consequences of these events are currently unknown.  A causal relationship has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	<span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in HIV-infected patients treated with combination antiretroviral therapy, including VIREAD. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> [such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jirovecii</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (PCP), or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>], which may necessitate further evaluation and treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	Early Virologic Failure</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Clinical studies in HIV-infected patients have demonstrated that certain regimens that only contain three nucleoside reverse transcriptase inhibitors (NRTI) are generally less effective than triple drug regimens containing two NRTIs in combination with either a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor. In particular, early virological failure and high rates of resistance substitutions have been reported. Triple nucleoside regimens should therefore be used with caution. Patients on a therapy utilizing a triple nucleoside-only regimen should be carefully monitored and considered for treatment modification.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in other sections of the labeling:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span>/Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with Steatosis <span class="Italics">[See <a href="#Box">Boxed Warning</a>, <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li> Severe Acute Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>  <span class="Italics">[See <a href="#Box">Boxed Warning</a>, <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>New Onset or Worsening <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</li>
<li>Decreases in Bone Mineral Density <span class="Italics">[See <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span> <span class="Italics">[See <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Adverse Reactions from Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics Underline">Clinical Trials in Patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV Infection</span></span></p>
<p>More than 12,000 patients have been treated with VIREAD alone or in combination with other antiretroviral medicinal products for periods of 28 days to 215 weeks in clinical trials and expanded access studies. A total of 1,544 patients have received VIREAD 300 mg once daily in clinical trials; over 11,000 patients have received VIREAD in expanded access studies.</p>
<p>The most common adverse reactions (incidence ≥10%, Grades 2–4) identified from any of the 3 large controlled clinical trials include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Treatment-Naïve Patients</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 903 - Treatment-Emergent Adverse Reactions:</span>  The most common adverse reactions seen in a double-blind comparative controlled study in which 600 treatment-naïve patients received VIREAD (N=299) or stavudine (N=301) in combination with lamivudine and efavirenz for 144 weeks (Study 903) were mild to moderate gastrointestinal events and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</p>
<p>Mild adverse reactions (Grade 1) were common with a similar incidence in both arms, and included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. Selected treatment-emergent moderate to severe adverse reactions are summarized in Table 2. </p>
<a name="table2"></a><table width="80%">
<caption><span>Table 2 Selected Treatment-Emergent Adverse Reactions<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> (Grades 2–4) Reported in ≥5% in Any Treatment Group in Study 903 (0–144 Weeks)</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">VIREAD + 3TC + EFV</th>
<th class="Botrule Rrule" align="center">d4T + 3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=299</th>
<th class="Rrule" align="center">N=301</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span> represents a variety of investigator-described adverse events not a protocol-defined syndrome.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> includes <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event includes <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustular rash</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Body as a Whole</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">14%</td>
<td class="Rrule" align="center">17%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Lrule Rrule" align="center">13%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Lrule Rrule" align="center">7%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Digestive System</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">11%</td>
<td class="Rrule" align="center">13%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">9%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule Rrule" align="center">4%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">9%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left"><span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">Metabolic Disorders</span></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">Lipodystrophy</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule" align="left">Musculoskeletal</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">Nervous System</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule" align="center">11%</td>
<td class="Rrule" align="center">10%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr>
<td class="Lrule" align="left">Respiratory</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">Skin and Appendages</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event<a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a>
</td>
<td class="Lrule Rrule" align="center">18%</td>
<td class="Rrule" align="center">12%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Laboratory Abnormalities:</span>  With the exception of fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and fasting triglyceride elevations that were more common in the stavudine group (40% and 9%) compared with VIREAD (19% and 1%) respectively, laboratory abnormalities observed in this study occurred with similar frequency in the VIREAD and stavudine treatment arms. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 3.</p>
<a name="table3"></a><table width="80%">
<caption><span>Table 3 Grade 3/4 Laboratory Abnormalities Reported in ≥1% of VIREAD-Treated Patients in Study 903 (0–144 Weeks)</span></caption>
<col align="left" valign="middle" width="34%">
<col align="center" valign="middle" width="33%">
<col align="center" valign="middle" width="33%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">VIREAD + 3TC + EFV</th>
<th class="Botrule Rrule" align="center">d4T + 3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=299</th>
<th class="Rrule" align="center">N=301</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any ≥ Grade 3 Laboratory Abnormality</td>
<td class="Rrule" align="center">36%</td>
<td class="Rrule" align="center">42%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span><br> (&gt;240 mg/dL)</td>
<td class="Rrule" align="center">19%</td>
<td class="Rrule" align="center">40%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatine Kinase<br> (M: &gt;990 U/L)<br> (F:  &gt;845 U/L)</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Amylase (&gt;175 U/L)</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br> (M: &gt;180 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT<br> (M: &gt;215 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> (&gt;100 RBC/HPF)</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (&lt;750/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Fasting Triglycerides (&gt;750 mg/dL)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">9%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 934 - Treatment Emergent Adverse Reactions:</span> In Study 934, 511 antiretroviral-naïve patients received either VIREAD + EMTRIVA<span class="Sup">®</span> administered in combination with efavirenz (N=257) or zidovudine/lamivudine administered in combination with efavirenz (N=254). Adverse reactions observed in this study were generally consistent with those seen in previous studies in treatment-experienced or treatment-naïve patients (Table 4).</p>
<a name="table4"></a><table width="80%">
<caption><span>Table 4 Selected Treatment-Emergent Adverse Reactions<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a> (Grades 2–4) Reported in ≥5% in Any Treatment Group in Study 934 (0–144 Weeks)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">VIREAD<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a> + FTC + EFV</th>
<th class="Botrule Rrule" align="center">AZT/3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=257</th>
<th class="Rrule" align="center">N=254</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>From Weeks 96 to 144 of the study, patients received TRUVADA with efavirenz in place of VIREAD + EMTRIVA with efavirenz.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event includes <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, exfoliative <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">rash macular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculo-papular, <span class="product-label-link" type="condition" conceptid="135618" conceptname="Pruritic rash">rash pruritic</span>, and <span class="product-label-link" type="condition" conceptid="4196499" conceptname="Vesicular eruption">rash vesicular</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorder</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">2%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">General Disorders and Administration Site Condition</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infections</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Psychiatric Disorders</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule Rrule" align="center">5%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Toprule" align="left">Skin and Subcutaneous Tissue Disorders</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Rrule Toprule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event<a name="footnote-reference-9" href="#footnote-9" class="Sup">‡</a>
</td>
<td class="Lrule Rrule" align="center">7%</td>
<td class="Rrule" align="center">9%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Laboratory Abnormalities:</span>  Laboratory abnormalities observed in this study were generally consistent with those seen in previous studies (Table 5).</p>
<table width="80%">
<caption><span>Table 5 Significant Laboratory Abnormalities Reported in ≥1% of Patients in Any Treatment Group in Study 934 (0–144 Weeks)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="30%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center">VIREAD<a name="footnote-reference-10" href="#footnote-10" class="Sup">*</a> + FTC + EFV</th>
<th class="Botrule Rrule" align="center">AZT/3TC + EFV</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">N=257</th>
<th class="Rrule" align="center">N=254</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-10" href="#footnote-reference-10">*</a></dt>
<dd>From Weeks 96 to 144 of the study, patients received TRUVADA with efavirenz in place of VIREAD + EMTRIVA with efavirenz.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any ≥ Grade 3 Laboratory Abnormality</td>
<td class="Rrule" align="center">30%</td>
<td class="Rrule" align="center">26%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (&gt;240 mg/dL)</td>
<td class="Rrule" align="center">22%</td>
<td class="Rrule" align="center">24%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatine Kinase<br> (M: &gt;990 U/L)<br> (F:  &gt;845 U/L)</td>
<td class="Rrule" align="center">9%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Amylase (&gt;175 U/L)</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Alkaline Phosphatase (&gt;550 U/L)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br> (M: &gt;180 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT<br> (M: &gt;215 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Hemoglobin (&lt;8.0 mg/dL)</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> (&gt;250 mg/dL)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> (&gt;75 RBC/HPF)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span> (≥3+)</td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (&lt;750/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Fasting Triglycerides (&gt;750 mg/dL)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Treatment-Experienced Patients</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Treatment-Emergent Adverse </span><span class="Italics">Reactions:</span>  The adverse reactions seen in treatment experienced patients were generally consistent with those seen in treatment naïve patients including mild to moderate gastrointestinal events, such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>. Less than 1% of patients discontinued participation in the clinical studies due to gastrointestinal adverse reactions (Study 907).</p>
<p>A summary of moderate to severe, treatment-emergent adverse reactions that occurred during the first 48 weeks of Study 907 is provided in Table 6.</p>
<a name="table6"></a><table width="80%">
<caption><span>Table 6 Selected Treatment-Emergent Adverse Reactions<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a> (Grades 2–4) Reported in ≥3% in Any Treatment Group in Study 907 (0–48 Weeks)</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">VIREAD<br> (N=368)<br> (Week 0–24)</th>
<th class="Rrule" align="center">Placebo<br> (N=182)<br> (Week 0–24)</th>
<th class="Rrule" align="center">VIREAD<br> (N=368)<br> (Week 0–48)</th>
<th class="Rrule" align="center">Placebo Crossover to VIREAD<br> (N=170)<br> (Week 24–48)</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Frequencies of adverse reactions are based on all treatment-emergent adverse events, regardless of relationship to study drug.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span> includes <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuritis</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>.</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event includes <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustular rash</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Body as a Whole</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule" align="left">Digestive System</td>
<td class="Lrule Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">16%</td>
<td class="Rrule" align="center">11%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Respiratory</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nervous System</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuropathy</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>
</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Skin and Appendage</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> event<a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Musculoskeletal</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Metabolic</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span></td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">2%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Laboratory Abnormalities:</span>  Laboratory abnormalities observed in this study occurred with similar frequency in the VIREAD and placebo-treated groups. A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 7.</p>
<a name="table7"></a><table width="80%">
<caption><span>Table 7 Grade 3/4 Laboratory Abnormalities Reported in ≥1% of VIREAD-Treated Patients in Study 907 (0–48 Weeks)</span></caption>
<col align="left" valign="middle" width="28%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<col align="center" valign="middle" width="18%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center">VIREAD<br> (N=368)<br> (Week 0–24)</th>
<th class="Rrule" align="center">Placebo<br> (N=182)<br> (Week 0–24)</th>
<th class="Rrule" align="center">VIREAD<br> (N=368)<br> (Week 0–48)</th>
<th class="Rrule" align="center">Placebo Crossover to VIREAD<br> (N=170)<br> (Week 24–48)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any ≥ Grade 3 Laboratory Abnormality</td>
<td class="Rrule" align="center">25%</td>
<td class="Rrule" align="center">38%</td>
<td class="Rrule" align="center">35%</td>
<td class="Rrule" align="center">34%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Triglycerides (&gt;750 mg/dL)</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">13%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">9%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatine Kinase<br> (M: &gt;990U/L)<br> (F:  &gt;845 U/L)</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">14%</td>
<td class="Rrule" align="center">12%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Amylase (&gt;175 U/L)</td>
<td class="Rrule" align="center">6%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">7%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span> (≥3+)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br> (M: &gt;180 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">ALT<br> (M: &gt;215 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Glucose (&gt;250 U/L)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span> (&lt;750/mm<span class="Sup">3</span>)</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.11"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics Underline">Clinical Trials in Patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.12"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Treatment-Emergent Adverse Reactions:</span> In controlled clinical trials in patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, more patients treated with VIREAD experienced <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>: 9% with VIREAD versus 2% with HEPSERA.  Other treatment-emergent adverse reactions reported in &gt;5% of patients treated with VIREAD included: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.13"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Laboratory Abnormalities:</span> A summary of Grade 3 and 4 laboratory abnormalities is provided in Table 8.</p>
<table width="80%">
<caption><span>Table 8.          Grade 3/4 Laboratory Abnormalities Reported in ≥1% of VIREAD-Treated Patients in Studies 0102 and 0103 (0-48 Weeks)</span></caption>
<col align="left" width="50%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="center"><span class="Bold">VIREAD<br> (N=426)</span></th>
<th class="Rrule" align="center"><span class="Bold">HEPSERA<br> (N=215)</span></th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Any ≥ Grade 3 Laboratory Abnormality</td>
<td class="Rrule" align="center">19%</td>
<td class="Rrule" align="center">13%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Creatine Kinase<br> (M: &gt;990U/L)<br> (F:  &gt;845 U/L)</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Serum Amylase (&gt;175 U/L)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span> (≥3+)</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">&lt;1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AST<br> (M: &gt;180 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">4%</td>
<td class="Rrule" align="center">4%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">ALT<br> (M: &gt;215 U/L)<br> (F:  &gt;170 U/L)</td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">6%</td>
</tr>
</tbody>
</table>
<p>The overall incidence of on-treatment ALT elevations (defined as serum ALT &gt;2 × baseline and &gt;10 × ULN, with or without associated symptoms) was similar between VIREAD (2.6%) and HEPSERA (2%). ALT elevations generally occurred within the first 4–8 weeks of treatment and were accompanied by decreases in HBV DNA levels. No patient had evidence of decompensation. ALT flares typically resolved within 4 to 8 weeks without changes in study medication.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.14"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of VIREAD. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders</span><br><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span></p>
<p><span class="Italics">Respiratory, Thoracic</span>, <span class="Italics">and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, increased amylase, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p><span class="Italics">Hepatobiliary Disorders</span><br><span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">hepatic steatosis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, increased liver enzymes (most commonly AST, ALT gamma GT)</p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders</span><br><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span><br><span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (manifested as <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>), <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span></p>
<p><span class="Italics">Renal and Urinary Disorders</span><br><span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, proximal renal tubulopathy, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> (including acute cases), <span class="product-label-link" type="condition" conceptid="438476" conceptname="Nephrogenic diabetes insipidus">nephrogenic diabetes insipidus</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, increased creatinine, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions</span><br><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span></p>
<p>The following adverse reactions, listed under the body system headings above, may occur as a consequence of proximal renal tubulopathy: <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, <span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">hypophosphatemia</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">This section describes clinically relevant drug interactions with VIREAD. Drug interactions studies are described elsewhere in the labeling <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Didanosine</h2>
<p class="First">Coadministration of VIREAD and didanosine should be undertaken with caution and patients receiving this combination should be monitored closely for didanosine-associated adverse reactions. Didanosine should be discontinued in patients who develop didanosine-associated adverse reactions.</p>
<p>When administered with VIREAD, C<span class="Sub">max</span> and AUC of didanosine (administered as either the buffered or enteric-coated formulation) increased significantly <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The mechanism of this interaction is unknown. Higher didanosine concentrations could potentiate didanosine-associated adverse reactions, including <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>. Suppression of CD4<span class="Sup">+</span> cell counts has been observed in patients receiving tenofovir disoproxil fumarate (tenofovir DF) with didanosine 400 mg daily. </p>
<p>In adults weighing &gt;60 kg, the didanosine dose should be reduced to 250 mg when it is coadministered with VIREAD. Data are not available to recommend a dose adjustment of didanosine for patients weighing &lt;60 kg. When coadministered, VIREAD and didanosine EC may be taken under fasted conditions or with a light meal (&lt;400 kcal, 20% fat). Coadministration of didanosine buffered tablet formulation with VIREAD should be under fasted conditions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	Atazanavir </h2>
<p class="First">Atazanavir has been shown to increase tenofovir concentrations <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The mechanism of this interaction is unknown. Patients receiving atazanavir and VIREAD should be monitored for VIREAD-associated adverse reactions. VIREAD should be discontinued in patients who develop VIREAD-associated adverse reactions.</p>
<p>VIREAD decreases the AUC and C<span class="Sub">min </span>of atazanavir <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. When coadministered with VIREAD, it is recommended that atazanavir 300 mg is given with ritonavir 100 mg. Atazanavir without ritonavir should not be coadministered with VIREAD.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Lopinavir/Ritonavir</h2>
<p class="First">Lopinavir/ritonavir has been shown to increase tenofovir concentrations <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. The mechanism of this interaction is unknown. Patients receiving lopinavir/ritonavir and VIREAD should be monitored for VIREAD-associated adverse reactions. VIREAD should be discontinued in patients who develop VIREAD-associated adverse reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Drugs Affecting Renal Function</h2>
<p class="First">Since tenofovir is primarily eliminated by the kidneys <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>, coadministration of VIREAD with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of tenofovir and/or increase the concentrations of other renally eliminated drugs. Some examples include, but are not limited to cidofovir, acyclovir, valacyclovir, ganciclovir, and valganciclovir. Drugs that decrease renal function may also increase serum concentrations of tenofovir.</p>
<p>In the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, VIREAD should not be administered in combination with HEPSERA (adefovir dipivoxil).</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1	Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pregnancy Category B</span></p>
<p>Reproduction studies have been performed in rats and rabbits at doses up to 14 and 19 times the human dose based on body surface area comparisons and revealed no evidence of impaired fertility or harm to the fetus due to tenofovir. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, VIREAD should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiretroviral Pregnancy Registry</span>: To monitor fetal outcomes of pregnant women exposed to VIREAD, an Antiretroviral Pregnancy Registry has been established. Healthcare providers are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.4"></a><p></p>
<h2>8.3	Nursing Mothers</h2>
<p class="First"><span class="Bold">Nursing Mothers:  The Centers for Disease Control and Prevention recommend that HIV-1-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV-1. </span>Studies in rats have demonstrated that tenofovir is secreted in milk. It is not known whether tenofovir is excreted in human milk. Because of both the potential for HIV-1 transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breast-feed if they are receiving VIREAD.</span></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.5"></a><p></p>
<h2>8.4	Pediatric Use</h2>
<p class="First">Safety and effectiveness in patients less than 18 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.6"></a><p></p>
<h2>8.5	Geriatric Use</h2>
<p class="First">Clinical studies of VIREAD did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for the elderly patient should be cautious, keeping in mind the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.7"></a><p></p>
<h2>8.6	Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">It is recommended that the dosing interval for VIREAD be modified in patients with creatinine clearance &lt;50 mL/min or in patients with ESRD who require dialysis <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>, <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">Limited clinical experience at doses higher than the therapeutic dose of VIREAD 300 mg is available. In Study 901, 600 mg tenofovir disoproxil fumarate was administered to 8 patients orally for 28 days. No severe adverse reactions were reported. The effects of higher doses are not known.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary. </p>
<p>Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">VIREAD is the brand name for tenofovir disoproxil fumarate (a prodrug of tenofovir) which is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. Tenofovir exhibits activity against HIV-1 reverse transcriptase.</p>
<p>The chemical name of tenofovir disoproxil fumarate is 9-[(<span class="Italics">R</span>)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C<span class="Sub">19</span>H<span class="Sub">30</span>N<span class="Sub">5</span>O<span class="Sub">10</span>P • C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and a molecular weight of 635.52. It has the following structural formula:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-01.jpg"></p>
<p>Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in distilled water at 25 °C. It has an octanol/phosphate buffer (pH 6.5) partition coefficient (log p) of 1.25 at 25 °C.</p>
<p>VIREAD tablets are for oral administration. Each tablet contains 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, and the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The tablets are coated with Opadry II Y–30–10671–A, which contains FD&amp;C blue #2 aluminum lake, hydroxypropyl methylcellulose 2910, lactose monohydrate, titanium dioxide, and triacetin.</p>
<p>In this insert, all dosages are expressed in terms of tenofovir disoproxil fumarate except where otherwise noted.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">Tenofovir disoproxil fumarate is an antiviral drug <span class="Italics">[See <a href="#S12.4">Clinical Pharmacology (12.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3	Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of tenofovir disoproxil fumarate have been evaluated in healthy volunteers and HIV-1 infected individuals. Tenofovir pharmacokinetics are similar between these populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Absorption</span></p>
<p>VIREAD is a water soluble diester prodrug of the active ingredient tenofovir. The oral bioavailability of tenofovir from VIREAD in fasted patients is approximately 25%. Following oral administration of a single dose of VIREAD 300 mg to HIV-1 infected patients in the fasted state, maximum serum concentrations (C<span class="Sub">max</span>) are achieved in 1.0 ± 0.4 hrs. C<span class="Sub">max</span> and AUC values are 0.30 ± 0.09 µg/mL and 2.29 ± 0.69 µg<span class="Bold">∙</span>hr/mL, respectively.</p>
<p>The pharmacokinetics of tenofovir are dose proportional over a VIREAD dose range of 75 to 600 mg and are not affected by repeated dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Distribution</span></p>
<p>In vitro binding of tenofovir to human plasma or serum proteins is less than 0.7 and 7.2%, respectively, over the tenofovir concentration range 0.01 to 25 µg/mL. The volume of distribution at steady-state is 1.3 ± 0.6 L/kg and 1.2 ± 0.4 L/kg, following intravenous administration of tenofovir 1.0 mg/kg and 3.0 mg/kg.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Metabolism and Elimination</span></p>
<p>In vitro studies indicate that neither tenofovir disoproxil nor tenofovir are substrates of CYP enzymes. </p>
<p>Following IV administration of tenofovir, approximately 70–80% of the dose is recovered in the urine as unchanged tenofovir within 72 hours of dosing. Following single dose, oral administration of VIREAD, the terminal elimination half-life of tenofovir is approximately 17 hours. After multiple oral doses of VIREAD 300 mg once daily (under fed conditions), 32 ± 10% of the administered dose is recovered in urine over 24 hours.</p>
<p>Tenofovir is eliminated by a combination of glomerular filtration and active tubular secretion. There may be competition for elimination with other compounds that are also renally eliminated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Effects of Food on Oral Absorption</span></p>
<p>Administration of VIREAD following a high-fat meal (~700 to 1000 kcal containing 40 to 50% fat) increases the oral bioavailability, with an increase in tenofovir AUC<span class="Sub">0–</span><span class="Sub">∞</span> of approximately 40% and an increase in C<span class="Sub">max</span> of approximately 14%. However, administration of VIREAD with a light meal did not have a significant effect on the pharmacokinetics of tenofovir when compared to fasted administration of the drug. Food delays the time to tenofovir C<span class="Sub">max</span> by approximately 1 hour. C<span class="Sub">max</span> and AUC of tenofovir are 0.33 ± 0.12 µg/mL and 3.32 ± 1.37 µg<span class="Bold">∙</span>hr/mL following multiple doses of VIREAD 300 mg once daily in the fed state, when meal content was not controlled. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.7"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Special Populations</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Race:  </span>There were insufficient numbers from racial and ethnic groups other than Caucasian to adequately determine potential pharmacokinetic differences among these populations.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Gender:  </span>Tenofovir pharmacokinetics are similar in male and female patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.10"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Pediatric and Geriatric Patients:  </span>Pharmacokinetic studies have not been performed in children (&lt;18 years) or in the elderly (&gt;65 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.11"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>:  </span>The pharmacokinetics of tenofovir are altered in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. In patients with creatinine clearance &lt;50 mL/min or with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) requiring dialysis, C<span class="Sub">max</span>, and AUC<span class="Sub">0–</span><span class="Sub">∞</span> of tenofovir were increased (Table 9). It is recommended that the dosing interval for VIREAD be modified in patients with creatinine clearance &lt;50 mL/min or in patients with ESRD who require dialysis <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>.</p>
<a name="table8"></a><table width="100%">
<caption><span>Table 9 Pharmacokinetic Parameters (Mean ± SD) of Tenofovir<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a> in Patients with Varying Degrees of Renal Function</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Baseline Creatinine Clearance (mL/min)</th>
<th class="Rrule" align="center">&gt;80<br> (N=3)</th>
<th class="Rrule" align="center">50–80<br> (N=10)</th>
<th class="Rrule" align="center">30–49<br> (N=8)</th>
<th class="Rrule" align="center">12–29<br> (N=11)</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>300 mg, single dose of VIREAD</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td class="Rrule" align="center">0.34 ± 0.03</td>
<td class="Rrule" align="center">0.33 ± 0.06</td>
<td class="Rrule" align="center">0.37 ± 0.16</td>
<td class="Rrule" align="center">0.60 ± 0.19</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AUC<span class="Sub">0–</span><span class="Sub">∞</span> (µg∙hr/mL)</td>
<td class="Rrule" align="center">2.18 ± 0.26</td>
<td class="Rrule" align="center">3.06 ± 0.93</td>
<td class="Rrule" align="center">6.01 ± 2.50</td>
<td class="Rrule" align="center">15.98 ± 7.22</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">CL/F (mL/min)</td>
<td class="Rrule" align="center">1043.7 ± 115.4</td>
<td class="Rrule" align="center">807.7 ± 279.2</td>
<td class="Rrule" align="center">444.4 ± 209.8</td>
<td class="Rrule" align="center">177.0 ± 97.1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">CL<span class="Sub">renal </span>(mL/min)</td>
<td class="Rrule" align="center">243.5 ± 33.3</td>
<td class="Rrule" align="center">168.6 ± 27.5</td>
<td class="Rrule" align="center">100.6 ± 27.5</td>
<td class="Rrule" align="center">43.0 ± 31.2</td>
</tr>
</tbody>
</table>
<p>Tenofovir is efficiently removed by hemodialysis with an extraction coefficient of approximately 54%. Following a single 300 mg dose of VIREAD, a four-hour hemodialysis session removed approximately 10% of the administered tenofovir dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.12"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:  </span>The pharmacokinetics of tenofovir following a 300 mg single dose of VIREAD have been studied in non-HIV infected patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. There were no substantial alterations in tenofovir pharmacokinetics in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> compared with unimpaired patients. No change in VIREAD dosing is required in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.13"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Assessment of Drug Interactions</span></p>
<p>At concentrations substantially higher (~300-fold) than those observed in vivo, tenofovir did not inhibit in vitro drug metabolism mediated by any of the following human CYP isoforms: CYP3A4, CYP2D6, CYP2C9, or CYP2E1. However, a small (6%) but statistically significant reduction in metabolism of CYP1A substrate was observed. Based on the results of in vitro experiments and the known elimination pathway of tenofovir, the potential for CYP mediated interactions involving tenofovir with other medicinal products is low <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>VIREAD has been evaluated in healthy volunteers in combination with abacavir, atazanavir, didanosine, efavirenz, emtricitabine, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral contraceptives, ribavirin, saquinavir/ritonavir, and tacrolimus. Tables 10 and 11 summarize pharmacokinetic effects of coadministered drug on tenofovir pharmacokinetics and effects of VIREAD on the pharmacokinetics of coadministered drug.</p>
<a name="table9"></a><table width="100%">
<caption><span>Table 10 Drug Interactions:  Changes in Pharmacokinetic Parameters for Tenofovir<a name="footnote-reference-15" href="#footnote-15" class="Sup">*</a> in the Presence of the Coadministered Drug</span></caption>
<col align="left" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">% Change of Tenofovir Pharmacokinetic Parameters<a name="footnote-reference-16" href="#footnote-16" class="Sup">†</a><br> (90% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-15" href="#footnote-reference-15">*</a></dt>
<dd>Patients received VIREAD 300 mg once daily.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">†</a></dt>
<dd><p class="First">Increase = ↑; Decrease = ↓; No Effect = <img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg">; NC = Not Calculated</p></dd>
<dt><a name="footnote-17" href="#footnote-reference-17">‡</a></dt>
<dd>Reyataz Prescribing Information</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Abacavir</td>
<td class="Rrule" align="center">300 once</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">NC</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir<a name="footnote-reference-17" href="#footnote-17" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">400 once daily<br> × 14 days</td>
<td class="Rrule" align="center">33</td>
<td class="Rrule" align="center">↑ 14<br> (↑ 8 to ↑ 20)</td>
<td class="Rrule" align="center">↑ 24<br> (↑ 21 to ↑ 28)</td>
<td class="Rrule" align="center">↑ 22<br> (↑ 15 to ↑ 30)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine (enteric-coated)</td>
<td class="Rrule" align="center">400 once</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Didanosine (buffered)</td>
<td class="Rrule" align="center">250 or 400 once daily × 7 days</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Efavirenz </td>
<td class="Rrule" align="center">600 once daily <br> × 14 days</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Emtricitabine</td>
<td class="Rrule" align="center">200 once daily <br> × 7 days</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Entecavir</td>
<td class="Rrule" align="center">1 mg once daily × <br>10 days</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 three times daily × 7 days</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">↑ 14<br> (↓ 3 to ↑ 33)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lamivudine</td>
<td class="Rrule" align="center">150 twice daily <br> × 7 days</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lopinavir/Ritonavir </td>
<td class="Rrule" align="center">400/100 twice daily × 14 days</td>
<td class="Rrule" align="center">24</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">↑ 32<br> (↑ 25 to ↑ 38)</td>
<td class="Rrule" align="center">↑ 51<br> (↑ 37 to ↑ 66)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Nelfinavir</td>
<td class="Rrule" align="center">1250 twice daily<br> × 14 days</td>
<td class="Rrule" align="center">29</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Saquinavir/Ritonavir</td>
<td class="Rrule" align="center">1000/100 twice daily × 14 days</td>
<td class="Rrule" align="center">35</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">↑ 23<br>  (↑ 16 to ↑ 30)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tacrolimus</td>
<td class="Rrule" align="center">0.05 mg/kg twice daily × 7 days</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">↑ 13<br>(↑ 1 to ↑ 27)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
</tbody>
</table>
<p>Following multiple dosing to HIV- and HBV-negative subjects receiving either chronic methadone maintenance therapy or oral contraceptives, or single doses of ribavirin, steady state tenofovir pharmacokinetics were similar to those observed in previous studies, indicating lack of clinically significant drug interactions between these agents and VIREAD.</p>
<a name="table10"></a><table width="100%">
<caption><span>Table 11 Drug Interactions:  Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of VIREAD</span></caption>
<col align="left" valign="middle" width="21%">
<col align="center" valign="middle" width="21%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<col align="center" valign="middle" width="16%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Coadministered Drug</th>
<th class="Rrule" align="center" rowspan="2">Dose of Coadministered Drug (mg)</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="3">% Change of Coadministered Drug Pharmacokinetic Parameters<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a><br> (90% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
<th class="Rrule" align="center">C<span class="Sub">min</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd><p class="First">Increase = ↑; Decrease = ↓; No Effect = <img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg">; NA = Not Applicable</p></dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Reyataz Prescribing Information</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">‡</a></dt>
<dd>In HIV-infected patients, addition of tenofovir DF to atazanavir 300 mg plus ritonavir 100 mg, resulted in AUC and C<span class="Sub">min</span> values of atazanavir that were 2.3- and 4-fold higher than the respective values observed for atazanavir 400 mg when given alone.</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">§</a></dt>
<dd>R-(active), S- and total methadone exposures were equivalent when dosed alone or with VIREAD.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">¶</a></dt>
<dd>Individual subjects were maintained on their stable methadone dose. No pharmacodynamic alterations (opiate toxicity or withdrawal signs or symptoms) were reported.</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">#</a></dt>
<dd>Ethinyl estradiol and 17-deacetyl norgestimate (pharmacologically active metabolite) exposures were equivalent when dosed alone or with VIREAD.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">Þ</a></dt>
<dd>Increases in AUC and C<span class="Sub">min</span> are not expected to be clinically relevant; hence no dose adjustments are required when tenofovir DF and ritonavir-boosted saquinavir are coadministered.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Abacavir</td>
<td class="Rrule" align="center">300 once</td>
<td class="Rrule" align="center">8</td>
<td class="Rrule" align="center">↑ 12<br> (↓ 1 to ↑ 26)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir<a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">400 once daily<br> × 14 days</td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">↓ 21<br> (↓ 27 to ↓ 14)</td>
<td class="Rrule" align="center">↓ 25<br> (↓ 30 to ↓ 19)</td>
<td class="Rrule" align="center">↓ 40<br> (↓ 48 to ↓ 32)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Atazanavir<a href="#footnote-19" class="Sup">†</a>
</td>
<td class="Rrule" align="center">Atazanavir/ Ritonavir<br> 300/100 once daily<br> × 42 days</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">↓ 28<br> (↓ 50 to ↑ 5)</td>
<td class="Rrule" align="center">↓ 25<a name="footnote-reference-20" href="#footnote-20" class="Sup">‡</a><br> (↓ 42 to ↓ 3)</td>
<td class="Rrule" align="center">↓ 23<a href="#footnote-20" class="Sup">‡</a><br> (↓ 46 to ↑ 10)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Efavirenz </td>
<td class="Rrule" align="center">600 once daily <br> × 14 days</td>
<td class="Rrule" align="center">30</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Emtricitabine</td>
<td class="Rrule" align="center">200 once daily <br> × 7 days</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">↑ 20<br> (↑ 12 to ↑ 29)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Entecavir</td>
<td class="Rrule" align="center">1 mg once daily <br>× 10 days</td>
<td class="Rrule" align="center">28 </td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">↑ 13<br>(↑ 11 to ↑ 15)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Indinavir</td>
<td class="Rrule" align="center">800 three times daily × 7 days</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">↓ 11<br> (↓ 30 to ↑ 12)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lamivudine</td>
<td class="Rrule" align="center">150 twice daily<br> × 7 days</td>
<td class="Rrule" align="center">15</td>
<td class="Rrule" align="center">↓ 24<br> (↓  34 to ↓ 12)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Lopinavir</td>
<td class="Botrule Rrule" align="center" rowspan="2">Lopinavir/Ritonavir 400/100 twice daily × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2">24</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Methadone<a name="footnote-reference-21" href="#footnote-21" class="Sup">§</a>
</td>
<td class="Rrule" align="center">40–110 once daily <br> × 14 days<a name="footnote-reference-22" href="#footnote-22" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nelfinavir</td>
<td class="Botrule Rrule" align="center" rowspan="2">1250 twice daily<br> × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2">29</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">M8 metabolite</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Oral Contraceptives<a name="footnote-reference-23" href="#footnote-23" class="Sup">#</a>
</td>
<td class="Rrule" align="center">Ethinyl Estradiol/<br> Norgestimate (Ortho-Tricyclen) <br> once daily × 7 days</td>
<td class="Rrule" align="center">20</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ribavirin</td>
<td class="Rrule" align="center">600 once</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">NA</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Saquinavir</td>
<td class="Botrule Rrule" align="center" rowspan="2">Saquinavir/Ritonavir 1000/100 twice daily × 14 days</td>
<td class="Botrule Rrule" align="center" rowspan="2">32</td>
<td class="Rrule" align="center">↑ 22<br> (↑ 6 to ↑ 41)</td>
<td class="Rrule" align="center">↑ 29<a name="footnote-reference-24" href="#footnote-24" class="Sup">Þ</a><br> (↑ 12 to ↑ 48)</td>
<td class="Rrule" align="center">↑ 47<a href="#footnote-24" class="Sup">Þ</a><br> (↑ 23 to ↑ 76)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ritonavir</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">↑ 23<br> (↑ 3 to ↑ 46)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Tacrolimus</td>
<td class="Rrule" align="center">0.05 mg/kg twice<br>daily × 7 days</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
</tbody>
</table>
<p>Table 12 summarizes the drug interaction between VIREAD and didanosine. Coadministration of VIREAD and didanosine should be undertaken with caution <span class="Italics">[See <a href="#S7.1">Drug Interactions (7.1)</a>]</span>. When administered with multiple doses of VIREAD, the C<span class="Sub">max</span> and AUC of didanosine 400 mg increased significantly. The mechanism of this interaction is unknown. When didanosine 250 mg enteric-coated capsules were administered with VIREAD, systemic exposures to didanosine were similar to those seen with the 400 mg enteric-coated capsules alone under fasted conditions.</p>
<a name="table11"></a><table width="100%">
<caption><span>Table 12 Drug Interactions:  Pharmacokinetic Parameters for Didanosine in the Presence of VIREAD </span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Didanosine Dose (mg)/ Method of Administration</th>
<th class="Rrule" align="center" rowspan="2">VIREAD Method of Administration<a name="footnote-reference-25" href="#footnote-25" class="Sup">*</a>
</th>
<th class="Rrule" align="center" rowspan="2">N</th>
<th class="Botrule Rrule" align="center" colspan="2">% Difference (90% CI) vs. Didanosine  400 mg Alone, Fasted<a name="footnote-reference-26" href="#footnote-26" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">C<span class="Sub">max</span>
</th>
<th class="Rrule" align="center">AUC</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">*</a></dt>
<dd>Administration with food was with a light meal (~373 kcal, 20% fat).</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">†</a></dt>
<dd><p class="First">Increase = ↑; Decrease = ↓; No Effect = <img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></p></dd>
<dt><a name="footnote-27" href="#footnote-reference-27">‡</a></dt>
<dd>Includes 4 subjects weighing &lt;60 kg receiving ddI 250 mg.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Buffered tablets</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once daily<a name="footnote-reference-27" href="#footnote-27" class="Sup">‡</a>  × 7 days</td>
<td class="Rrule" align="center">Fasted 1 hour after didanosine</td>
<td class="Rrule" align="center">14</td>
<td class="Rrule" align="center">↑ 28<br> (↑ 11 to ↑ 48)</td>
<td class="Rrule" align="center">↑ 44<br> (↑ 31 to ↑ 59)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" colspan="2"><span class="Bold">Enteric coated capsules</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once, fasted</td>
<td class="Rrule" align="center">With food, 2 hours after didanosine</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">↑ 48<br> (↑ 25 to ↑ 76)</td>
<td class="Rrule" align="center">↑ 48<br> (↑ 31 to ↑ 67)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">400 once, with food</td>
<td class="Rrule" align="center">Simultaneously with didanosine</td>
<td class="Rrule" align="center">26</td>
<td class="Rrule" align="center">↑ 64<br> (↑ 41 to ↑ 89)</td>
<td class="Rrule" align="center">↑ 60<br> (↑ 44 to ↑ 79)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">250 once, fasted</td>
<td class="Rrule" align="center">With food, 2 hours after didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center">↓ 10<br> (↓ 22 to ↑ 3)</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">250 once, fasted</td>
<td class="Rrule" align="center">Simultaneously with didanosine</td>
<td class="Rrule" align="center">28</td>
<td class="Rrule" align="center"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-02.jpg"></td>
<td class="Rrule" align="center">↑ 14<br> (0 to ↑ 31)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left">250 once, with food</td>
<td class="Rrule Toprule" align="center">Simultaneously with didanosine</td>
<td class="Rrule Toprule" align="center">28</td>
<td class="Rrule Toprule" align="center">↓ 29<br> (↓ 39 to ↓ 18)</td>
<td class="Rrule Toprule" align="center">↓ 11<br> (↓ 23 to ↑ 2)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="S12.4"></a><a name="section-11.14"></a><p></p>
<h2>12.4	Microbiology</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.15"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Mechanism of Action</span></p>
<p>Tenofovir disoproxil fumarate is an acyclic nucleoside phosphonate diester analog of adenosine monophosphate. Tenofovir disoproxil fumarate requires initial diester hydrolysis for conversion to tenofovir and subsequent phosphorylations by cellular enzymes to form tenofovir diphosphate, an obligate chain terminator.  Tenofovir diphosphate inhibits the activity of HIV-1 reverse transcriptase and HBV polymerase by competing with the natural substrate deoxyadenosine 5'-triphosphate and, after incorporation into DNA, by DNA chain termination. Tenofovir diphosphate is a weak inhibitor of mammalian DNA polymerases α, β, and mitochondrial DNA polymerase γ.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.16"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics Underline">Activity against HIV</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.17"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiviral Activity</span></p>
<p>The antiviral activity of tenofovir against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, primary monocyte/macrophage cells and peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>. The EC<span class="Sub">50</span> (50% effective concentration) values for tenofovir were in the range of 0.04 µM to 8.5 µM. In drug combination studies of tenofovir with nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, zalcitabine, zidovudine), non-nucleoside reverse transcriptase inhibitors (delavirdine, efavirenz, nevirapine), and protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, saquinavir), additive to synergistic effects were observed. Tenofovir displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O (EC<span class="Sub">50</span> values ranged from 0.5 µM to 2.2 µM) and <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> specific activity against HIV-2 (EC<span class="Sub">50</span> values ranged from 1.6 µM to 5.5 µM).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.18"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Resistance</span></p>
<p>HIV-1 isolates with reduced susceptibility to tenofovir have been selected in cell culture. These viruses expressed a K65R substitution in reverse transcriptase and showed a 2–4 fold reduction in susceptibility to tenofovir.</p>
<p>In Study 903 of treatment-naïve patients (VIREAD + lamivudine + efavirenz versus stavudine + lamivudine + efavirenz) <span class="Italics">[See <a href="#S14.1">Clinical Studies (14.1)</a>]</span>, genotypic analyses of isolates from patients with virologic failure through Week 144 showed development of efavirenz and lamivudine resistance-associated substitutions to occur most frequently and with no difference between the treatment arms. The K65R substitution occurred in 8/47 (17%) analyzed patient isolates on the VIREAD arm and in 2/49 (4%) analyzed patient isolates on the stavudine arm. Of the 8 patients whose virus developed K65R in the VIREAD arm through 144 weeks, 7 of these occurred in the first 48 weeks of treatment and one at Week 96. Other substitutions resulting in resistance to VIREAD were not identified in this study.</p>
<p>In Study 934 of treatment-naïve patients (VIREAD + EMTRIVA + efavirenz versus zidovudine (AZT)/lamivudine (3TC) + efavirenz) <span class="Italics">[See <a href="#S14.1">Clinical Studies (14.1)</a>]</span>, genotypic analysis performed on HIV-1 isolates from all confirmed virologic failure patients with &gt;400 copies/mL of HIV-1 RNA at Week 144 or early discontinuation showed development of efavirenz resistance-associated substitutions occurred most frequently and was similar between the two treatment arms. The M184V substitution, associated with resistance to EMTRIVA and lamivudine, was observed in 2/19 analyzed patient isolates in the VIREAD + EMTRIVA group and in 10/29 analyzed patient isolates in the zidovudine/lamivudine group. Through 144 weeks of Study 934, no patients have developed a detectable K65R substitution in their HIV-1 as analyzed through standard genotypic analysis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.19"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Cross Resistance</span></p>
<p>Cross-resistance among certain reverse transcriptase inhibitors has been recognized. The K65R substitution selected by tenofovir is also selected in some HIV-1 infected subjects treated with abacavir, didanosine, or zalcitabine. HIV-1 isolates with this mutation also show reduced susceptibility to emtricitabine and lamivudine. Therefore, cross-resistance among these drugs may occur in patients whose virus harbors the K65R substitution. HIV-1 isolates from patients (N=20) whose HIV-1 expressed a mean of 3 zidovudine-associated reverse transcriptase substitutions (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N), showed a 3.1-fold decrease in the susceptibility to tenofovir. Multinucleoside resistant HIV-1 with a T69S double insertion substitution in the reverse transcriptase showed reduced susceptibility to tenofovir.</p>
<p>In Studies 902 and 907 conducted in treatment-experienced patients (VIREAD + Standard Background Therapy (SBT) compared to Placebo + SBT) <span class="Italics">[See <a href="#S14.1">Clinical Studies (14.1)</a>]</span>, 14/304 (5%) of the VIREAD-treated patients with virologic failure through Week 96 had &gt;1.4-fold (median 2.7-fold) reduced susceptibility to tenofovir. Genotypic analysis of the baseline and failure isolates showed the development of the K65R substitution in the HIV-1 reverse transcriptase gene.</p>
<p>The virologic response to VIREAD therapy has been evaluated with respect to baseline viral genotype (N=222) in treatment-experienced patients participating in Studies 902 and 907. </p>
<p>In these clinical studies, 94% of the participants evaluated had baseline HIV-1 isolates expressing at least one NRTI mutation. These included resistance substitutions associated with zidovudine (M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E/N), the abacavir/emtricitabine/lamivudine resistance-associated substitution (M184V), and others. In addition the majority of participants evaluated had substitutions associated with either PI or NNRTI use. Virologic responses for patients in the genotype substudy were similar to the overall study results.</p>
<p>Several exploratory analyses were conducted to evaluate the effect of specific substitutions and substitutional patterns on virologic outcome. Because of the large number of potential comparisons, statistical testing was not conducted. Varying degrees of cross-resistance of VIREAD to pre-existing zidovudine resistance-associated substitutions were observed and appeared to depend on the number of specific substitutions. VIREAD-treated patients whose HIV-1 expressed 3 or more zidovudine resistance-associated substitutions that included either the M41L or L210W reverse transcriptase substitution showed reduced responses to VIREAD therapy; however, these responses were still improved compared with placebo. The presence of the D67N, K70R, T215Y/F, or K219Q/E/N substitution did not appear to affect responses to VIREAD therapy. </p>
<p>In the protocol defined analyses, virologic response to VIREAD was not reduced in patients with HIV-1 that expressed the abacavir/emtricitabine/lamivudine resistance-associated M184V substitution. In the presence of zidovudine resistance-associated substitutions, the M184V substitution did not affect the mean HIV-1 RNA responses to VIREAD treatment. HIV-1 RNA responses among these patients were durable through Week 48.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.20"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Studies 902 and 907 Phenotypic Analyses</span></p>
<p>The virologic response to VIREAD therapy has been evaluated with respect to baseline phenotype (N=100) in treatment-experienced patients participating in two controlled trials. Phenotypic analysis of baseline HIV-1 from patients in these studies demonstrated a correlation between baseline susceptibility to VIREAD and response to VIREAD therapy. Table 13 summarizes the HIV-1 RNA response by baseline VIREAD susceptibility.</p>
<a name="table12"></a><table width="80%">
<caption><span>Table 13 HIV-1 RNA Response at Week 24 by Baseline VIREAD Susceptibility (Intent-To-Treat)<a name="footnote-reference-28" href="#footnote-28" class="Sup">*</a></span></caption>
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Baseline VIREAD Susceptibility<a name="footnote-reference-29" href="#footnote-29" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Change in HIV-1 RNA<a name="footnote-reference-30" href="#footnote-30" class="Sup">‡</a> (N)</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-28" href="#footnote-reference-28">*</a></dt>
<dd>Tenofovir susceptibility was determined by recombinant phenotypic Antivirogram assay (Virco).</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">†</a></dt>
<dd>Fold change in susceptibility from wild-type.</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">‡</a></dt>
<dd>Average HIV-1 RNA change from baseline through Week 24 (DAVG<span class="Sub">24</span>) in log<span class="Sub">10</span> copies/mL.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">&lt;1</td>
<td class="Rrule" align="center">-0.74 (35)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">&gt;1 and ≤3</td>
<td class="Rrule" align="center">-0.56 (49)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">&gt;3 and ≤4</td>
<td class="Rrule" align="center">-0.3 (7)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">&gt;4</td>
<td class="Rrule" align="center">-0.12 (9)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.21"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics Underline">Activity against HBV</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.22"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Antiviral Activity</span></p>
<p>The antiviral activity of tenofovir against HBV was assessed in the HepG2 2.2.15 cell line.  The EC<span class="Sub">50</span> values for tenofovir ranged from 0.14 to 1.5 µM, with CC<span class="Sub">50 </span>(50% cytotoxicity concentration) values &gt;100 µM.  In cell culture combination antiviral activity studies of tenofovir with the nucleoside anti-HBV reverse transcriptase inhibitors emtricitabine, entecavir, lamivudine and telbivudine, no antagonistic activity was observed.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.23"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Resistance</span></p>
<p>Out of 426 HBeAg negative and HBeAg positive patients, 39 patients had serum HBV DNA &gt;400 copies/mL at Week 48. Genotypic data from paired baseline and on treatment isolates were available for 28 of the 39 patients. No specific amino acid substitutions occurred in these subjects' isolates at sufficient frequency to establish an association with tenofovir resistance.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.24"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Cross Resistance </span></p>
<p>Cross-resistance has been observed among HBV reverse transcriptase inhibitors.</p>
<p>In cell based assays, HBV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> expressing the rtV173L,  rtL180M, and rtM204I/V substitutions associated with resistance to lamivudine and telbivudine showed a susceptibility to tenofovir ranging from 0.7 to 3.4-fold that of wild type virus. The rtL180M and rtM204I/V double substitutions conferred 3.4-fold reduced susceptibility to tenofovir.</p>
<p>HBV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> expressing the rtL180M, rtT184G, rtS202G/I, rtM204V, and rtM250V  substitutions associated with resistance to entecavir showed a susceptibility to tenofovir ranging from 0.6 to 6.9-fold that of wild type virus.  An HBV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> expressing rtL180M, rtT184G, rtS202I and rtM204V together had a 6.9-fold reduction in susceptibility to tenofovir.</p>
<p>HBV <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> expressing the adefovir-associated resistance substitutions rtA181V and/or rtN236T showed reductions in susceptibility to tenofovir ranging from 2.9 to 10-fold that of wild type virus.  </p>
<p><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> containing the rtA181T substitution showed changes in susceptibility to tenofovir ranging from 0.9 to 1.5-fold that of wild type virus.   </p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term oral carcinogenicity studies of tenofovir disoproxil fumarate in mice and rats were carried out at exposures up to approximately 16 times (mice) and 5 times (rats) those observed in humans at the therapeutic dose for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. At the high dose in female mice, liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased at exposures 16 times that in humans. In rats, the study was negative for carcinogenic findings at exposures up to 5 times that observed in humans at the therapeutic dose.</p>
<p>Tenofovir disoproxil fumarate was mutagenic in the in vitro mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and negative in an in vitro bacterial mutagenicity test (Ames test). In an in vivo mouse micronucleus assay, tenofovir disoproxil fumarate was negative when administered to male mice.</p>
<p>There were no effects on fertility, mating performance or early embryonic development when tenofovir disoproxil fumarate was administered to male rats at a dose equivalent to 10 times the human dose based on body surface area comparisons for 28 days prior to mating and to female rats for 15 days prior to mating through day seven of gestation. There was, however, an alteration of the estrous cycle in female rats.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2	Animal Toxicology and/or Pharmacology</h2>
<p class="First">Tenofovir and tenofovir disoproxil fumarate administered in toxicology studies to rats, dogs, and monkeys at exposures (based on AUCs) greater than or equal to 6 fold those observed in humans caused bone toxicity. In monkeys the bone toxicity was diagnosed as <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>. <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">Osteomalacia</span> observed in monkeys appeared to be reversible upon dose reduction or discontinuation of tenofovir. In rats and dogs, the bone toxicity manifested as reduced bone mineral density. The mechanism(s) underlying bone toxicity is unknown. </p>
<p>Evidence of renal toxicity was noted in 4 animal species. Increases in serum creatinine, BUN, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, phosphaturia, and/or calciuria and decreases in serum phosphate were observed to varying degrees in these animals. These toxicities were noted at exposures (based on AUCs) 2–20 times higher than those observed in humans. The relationship of the renal abnormalities, particularly the phosphaturia, to the bone toxicity is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1	Clinical Efficacy in Patients with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Treatment-Naïve Patients</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 903</span></p>
<p>Data through 144 weeks are reported for Study 903, a double-blind, active-controlled multicenter study comparing VIREAD (300 mg once daily) administered in combination with lamivudine and efavirenz versus stavudine (d4T), lamivudine, and efavirenz in 600 antiretroviral-naïve patients. Patients had a mean age of 36 years (range 18–64), 74% were male, 64% were Caucasian and 20% were Black. The mean baseline CD4<span class="Sup">+</span> cell count was 279 cells/mm<span class="Sup">3</span> (range 3–956) and median baseline plasma HIV-1 RNA was 77,600 copies/mL (range 417–5,130,000). Patients were stratified by baseline HIV-1 RNA and CD4<span class="Sup">+</span> cell count. Forty-three percent of patients had baseline viral loads &gt;100,000 copies/mL and 39% had CD4<span class="Sup">+</span> cell counts &lt;200 cells/mm<span class="Sup">3</span>. Treatment outcomes through 48 and 144 weeks are presented in Table 14.</p>
<a name="table13"></a><table width="100%">
<caption><span>Table 14 Outcomes of Randomized Treatment at Week 48 and 144 (Study 903)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left"></th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 48</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 144</th>
</tr>
<tr class="Botrule Last">
<th class="Lrule Rrule" align="left">Outcomes</th>
<th align="center">VIREAD+3TC<br> +EFV<br> (N=299)</th>
<th class="Lrule Rrule" align="center">d4T+3TC<br> +EFV<br> (N=301)</th>
<th class="Rrule" align="center">VIREAD+3TC<br> +EFV<br> (N=299)</th>
<th class="Rrule" align="center">d4T+3TC<br> +EFV<br> (N=301)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-31" href="#footnote-reference-31">*</a></dt>
<dd>Patients achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Week 48 and 144.</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">†</a></dt>
<dd>Includes confirmed viral rebound and failure to achieve confirmed &lt;400 copies/mL through Week 48 and 144.</dd>
<dt><a name="footnote-33" href="#footnote-reference-33">‡</a></dt>
<dd>Includes lost to follow-up, patient's withdrawal, noncompliance, protocol violation and other reasons.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Responder<a name="footnote-reference-31" href="#footnote-31" class="Sup">*</a>
</td>
<td align="center">79%</td>
<td class="Lrule Rrule" align="center">82%</td>
<td class="Rrule" align="center">68%</td>
<td class="Rrule" align="center">62%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Virologic failure<a name="footnote-reference-32" href="#footnote-32" class="Sup">†</a>
</td>
<td align="center">6%</td>
<td class="Lrule Rrule" align="center">4%</td>
<td class="Rrule" align="center">10%</td>
<td class="Rrule" align="center">8%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Rebound</td>
<td align="center">5%</td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">7%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Never suppressed </td>
<td align="center">0%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Added an antiretroviral agent</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">&lt;1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">&lt;1%</td>
<td class="Rrule" align="center">2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Discontinued due to adverse event</td>
<td align="center">6%</td>
<td class="Lrule Rrule" align="center">6%</td>
<td class="Rrule" align="center">8%</td>
<td class="Rrule" align="center">13%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Discontinued for other reasons<a name="footnote-reference-33" href="#footnote-33" class="Sup">‡</a>
</td>
<td align="center">8%</td>
<td class="Lrule Rrule" align="center">7%</td>
<td class="Rrule" align="center">14%</td>
<td class="Rrule" align="center">15%</td>
</tr>
</tbody>
</table>
<p>Achievement of plasma HIV-1 RNA concentrations of less than 400 copies/mL at Week 144 was similar between the two treatment groups for the population stratified at baseline on the basis of HIV-1 RNA concentration (&gt; or ≤100,000 copies/mL) and CD4<span class="Sup">+</span> cell count (&lt; or ≥200 cells/mm<span class="Sup">3</span>). Through 144 weeks of therapy, 62% and 58% of patients in the VIREAD and stavudine arms, respectively achieved and maintained confirmed HIV-1 RNA &lt;50 copies/mL. The mean increase from baseline in CD4<span class="Sup">+</span> cell count was 263 cells/mm<span class="Sup">3</span> for the VIREAD arm and 283 cells/mm<span class="Sup">3</span> for the stavudine arm.</p>
<p>Through 144 weeks, 11 patients in the VIREAD group and 9 patients in the stavudine group experienced a new CDC Class C event.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.4"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 934</span></p>
<p>Data through 144 weeks are reported for Study 934, a randomized, open-label, active-controlled multicenter study comparing emtricitabine + VIREAD administered in combination with efavirenz versus zidovudine/lamivudine fixed-dose combination administered in combination with efavirenz in 511 antiretroviral-naïve patients. From Weeks 96 to 144 of the study, patients received a fixed-dose combination of emtricitabine and tenofovir DF with efavirenz in place of emtricitabine + VIREAD with efavirenz. Patients had a mean age of 38 years (range 18–80), 86% were male, 59% were Caucasian and 23% were Black. The mean baseline CD4<span class="Sup">+</span> cell count was 245 cells/mm<span class="Sup">3</span> (range 2–1191) and median baseline plasma HIV-1 RNA was 5.01 log<span class="Sub">10</span> copies/mL (range 3.56–6.54). Patients were stratified by baseline CD4<span class="Sup">+ </span>cell count (&lt; or ≥200 cells/mm<span class="Sup">3</span>); 41% had CD4<span class="Sup">+ </span>cell counts &lt;200 cells/mm<span class="Sup">3</span> and 51% of patients had baseline viral loads &gt;100,000 copies/mL. Treatment outcomes through 48 and 144 weeks for those patients who did not have efavirenz resistance at baseline are presented in Table 15.</p>
<a name="table14"></a><table width="100%">
<caption><span>Table 15 Outcomes of Randomized Treatment at Week 48 and 144 (Study 934)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Outcomes</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 48</th>
<th class="Botrule Rrule" align="center" colspan="2">At Week 144</th>
</tr>
<tr class="Last">
<th align="center" valign="bottom">FTC<br> +VIREAD<br> +EFV<br> (N=244)</th>
<th class="Lrule Rrule" align="center" valign="bottom">AZT/3TC<br> +EFV<br> (N=243)</th>
<th class="Rrule" align="center" valign="bottom">FTC<br> +VIREAD<br> +EFV<br> (N=227)<a name="footnote-reference-34" href="#footnote-34" class="Sup">*</a>
</th>
<th class="Rrule" align="center" valign="bottom">AZT/3TC<br> +EFV<br> (N=229)<a href="#footnote-34" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-34" href="#footnote-reference-34">*</a></dt>
<dd>Patients who were responders at Week 48 or Week 96 (HIV-1 RNA &lt;400 copies/mL) but did not consent to continue study after Week 48 or Week 96 were excluded from analysis.</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">†</a></dt>
<dd>Patients achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL through Weeks 48 and 144.</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">‡</a></dt>
<dd>Includes confirmed viral rebound and failure to achieve confirmed &lt;400 copies/mL through Weeks 48 and 144.</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">§</a></dt>
<dd>Includes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other reasons.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">Responder<a name="footnote-reference-35" href="#footnote-35" class="Sup">†</a>
</td>
<td align="center">84%</td>
<td class="Lrule Rrule" align="center">73%</td>
<td class="Rrule" align="center">71%</td>
<td class="Rrule" align="center">58%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Virologic failure<a name="footnote-reference-36" href="#footnote-36" class="Sup">‡</a>
</td>
<td align="center">2%</td>
<td class="Lrule Rrule" align="center">4%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">6%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Rebound</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">3%</td>
<td class="Rrule" align="center">2%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Never suppressed</td>
<td align="center">0%</td>
<td class="Lrule Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  Change in antiretroviral regimen</td>
<td align="center">1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">&lt;1%</td>
<td class="Lrule Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
<td class="Rrule" align="center">1%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Discontinued due to adverse event</td>
<td align="center">4%</td>
<td class="Lrule Rrule" align="center">9%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">12%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Discontinued for other reasons<a name="footnote-reference-37" href="#footnote-37" class="Sup">§</a>
</td>
<td align="center">10%</td>
<td class="Lrule Rrule" align="center">14%</td>
<td class="Rrule" align="center">20%</td>
<td class="Rrule" align="center">22%</td>
</tr>
</tbody>
</table>
<p>Through Week 48, 84% and 73% of patients in the emtricitabine + VIREAD group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA &lt;400 copies/mL (71% and 58% through Week 144). The difference in the proportion of patients who achieved and maintained HIV-1 RNA &lt;400 copies/mL through 48 weeks largely results from the higher number of discontinuations due to adverse events and other reasons in the zidovudine/lamivudine group in this open-label study. In addition, 80% and 70% of patients in the emtricitabine + VIREAD group and the zidovudine/lamivudine group, respectively, achieved and maintained HIV-1 RNA &lt;50 copies/mL through Week 48 (64% and 56% through Week 144). The mean increase from baseline in CD4<span class="Sup">+</span> cell count was 190 cells/mm<span class="Sup">3</span> in the EMTRIVA + VIREAD group and 158 cells/mm<span class="Sup">3</span> in the zidovudine/lamivudine group at Week 48 (312 and 271 cells/mm<span class="Sup">3</span> at Week 144).</p>
<p>Through 48 weeks, 7 patients in the emtricitabine + VIREAD group and 5 patients in the zidovudine/lamivudine group experienced a new CDC Class C event (10 and 6 patients through 144 weeks).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.5"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Treatment-Experienced Patients</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.6"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Study 907</span></p>
<p>Study 907 was a 24-week, double-blind placebo-controlled multicenter study of VIREAD added to a stable background regimen of antiretroviral agents in 550 treatment-experienced patients. After 24 weeks of blinded study treatment, all patients continuing on study were offered open-label VIREAD for an additional 24 weeks. Patients had a mean baseline CD4<span class="Sup">+</span> cell count of 427 cells/mm<span class="Sup">3 </span>(range 23–1385), median baseline plasma HIV-1 RNA of 2340 (range 50–75,000) copies/mL, and mean duration of prior HIV-1 treatment was 5.4 years. Mean age of the patients was 42 years, 85% were male and 69% were Caucasian, 17% Black and 12% Hispanic.</p>
<p>Changes from baseline in log<span class="Sub">10</span> copies/mL plasma HIV-1 RNA levels over time up to Week 48 are presented below in Figure 1.</p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=viread-03.jpg"></p>
<p>The percent of patients with HIV-1 RNA &lt;400 copies/mL and outcomes of patients through 48 weeks are summarized in Table 16.</p>
<a name="table15"></a><table width="100%">
<caption><span>Table 16 Outcomes of Randomized Treatment (Study 907)</span></caption>
<col align="left" valign="middle" width="40%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<col align="center" valign="middle" width="15%">
<thead>
<tr class="First">
<th class="Lrule Rrule" align="left" rowspan="2">Outcomes</th>
<th class="Botrule Rrule" align="center" colspan="2">0–24 weeks</th>
<th class="Botrule Rrule" align="center">0–48 weeks</th>
<th class="Botrule Rrule" align="center">24–48 weeks</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">VIREAD <br> (N=368)</th>
<th class="Rrule" align="center">Placebo<br> (N=182)</th>
<th class="Rrule" align="center">VIREAD<br> (N=368)</th>
<th class="Rrule" align="center">Placebo Crossover<br> to VIREAD<br> (N=170)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-38" href="#footnote-reference-38">*</a></dt>
<dd>Patients with HIV-1 RNA &lt;400 copies/mL and no prior study drug discontinuation at Week 24 and 48 respectively.</dd>
<dt><a name="footnote-39" href="#footnote-reference-39">†</a></dt>
<dd>Patients with HIV-1 RNA ≥400 copies/mL efficacy failure or missing HIV-1 RNA at Week 24 and 48 respectively.</dd>
<dt><a name="footnote-40" href="#footnote-reference-40">‡</a></dt>
<dd>Includes lost to follow-up, patient withdrawal, noncompliance, protocol violation and other reasons.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">HIV-1 RNA &lt;400 copies/mL<a name="footnote-reference-38" href="#footnote-38" class="Sup">*</a>
</td>
<td class="Rrule" align="center">40%</td>
<td class="Rrule" align="center">11%</td>
<td class="Rrule" align="center">28%</td>
<td class="Rrule" align="center">30%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Virologic failure<a name="footnote-reference-39" href="#footnote-39" class="Sup">†</a>
</td>
<td class="Rrule" align="center">53%</td>
<td class="Rrule" align="center">84%</td>
<td class="Rrule" align="center">61%</td>
<td class="Rrule" align="center">64%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Discontinued due to adverse event</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">Discontinued for other reasons<a name="footnote-reference-40" href="#footnote-40" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">3%</td>
<td class="Rrule" align="center">5%</td>
<td class="Rrule" align="center">1%</td>
</tr>
</tbody>
</table>
<p>At 24 weeks of therapy, there was a higher proportion of patients in the VIREAD arm compared to the placebo arm with HIV-1 RNA &lt;50 copies/mL (19% and 1%, respectively). Mean change in absolute CD4<span class="Sup">+</span> cell counts by Week 24 was +11 cells/mm<span class="Sup">3</span> for the VIREAD group and -5 cells/mm<span class="Sup">3</span> for the placebo group. Mean change in absolute CD4<span class="Sup">+</span> cell counts by Week 48 was +4 cells/mm<span class="Sup">3</span> for the VIREAD group.</p>
<p>Through Week 24, one patient in the VIREAD group and no patients in the placebo arm experienced a new CDC Class C event.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.7"></a><p></p>
<h2>14.2	Clinical Efficacy in Patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</h2>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.8"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">HBeAg-Negative <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</span></p>
<p>Study 0102 was a Phase 3, randomized, double-blind, active-controlled study of VIREAD 300 mg compared to HEPSERA 10 mg in 375 HBeAg- (anti-HBe+) patients with compensated liver function, the majority of whom were nucleoside-naïve.  The mean age of patients was 44 years, 77% were male, 25% were Asian, 65% were Caucasian, 17% had previously received alpha-interferon therapy and 18% were nucleoside-experienced (16% had prior lamivudine experience).  At baseline, patients had a mean Knodell necroinflammatory score of 7.8; mean plasma HBV DNA was 6.9 log<span class="Sub">10</span> copies/mL; and mean serum ALT was 140 U/L.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.9"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">HBeAg-Positive <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B</span></p>
<p>Study 0103 was a Phase 3, randomized, double-blind, active-controlled study of VIREAD 300 mg compared to HEPSERA 10 mg in 266 HBeAg+ nucleoside-naïve patients with compensated liver function.  The mean age of patients was 34 years, 69% were male, 36% were Asian, 52% were Caucasian, 16% had previously received alpha-interferon therapy, and &lt;5% were nucleoside experienced.  At baseline, patients had a mean Knodell necroinflammatory score of 8.4; mean plasma HBV DNA was 8.7 log<span class="Sub">10</span> copies /mL; and mean serum ALT was 147 U/L. </p>
<p>The primary data analysis was conducted after all patients reached 48 weeks of treatment and results are summarized below.</p>
<p>The primary efficacy endpoint in both studies was complete response to treatment defined as HBV DNA &lt;400 copies/mL and Knodell necroinflammatory score improvement of at least 2 points, without worsening in Knodell <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> at Week 48 (Table 17).  </p>
<table width="85%">
<caption><span>Table 17 Histological, Virological, Biochemical, and Serological Response at Week 48</span></caption>
<col align="left" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center" colspan="2">0102 (HBeAg-)</th>
<th align="center" colspan="2">0103 (HBeAg+)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">VIREAD<br> (N=250)</th>
<th class="Rrule" align="center">HEPSERA<br> (N=125)</th>
<th class="Rrule" align="center">VIREAD<br> (N=176)</th>
<th align="center">HEPSERA<br> (N=90)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-41" href="#footnote-reference-41">*</a></dt>
<dd>Knodell necroinflammatory score improvement of at least 2 points without worsening in Knodell <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>.</dd>
<dt><a name="footnote-42" href="#footnote-reference-42">†</a></dt>
<dd>The population used for analysis of ALT normalization included only patients with ALT above ULN at baseline.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">‡</a></dt>
<dd>NA = Not Applicable</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="Bold">Complete  Response</span></td>
<td class="Rrule" align="center">71%</td>
<td class="Rrule" align="center">49%</td>
<td class="Rrule" align="center">67%</td>
<td align="center">12%</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Histology</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Histological Response<a name="footnote-reference-41" href="#footnote-41" class="Sup">*</a>
</td>
<td class="Rrule" align="center">72%<br>
</td>
<td class="Rrule" align="center">69%</td>
<td class="Rrule" align="center">74%</td>
<td align="center">68%</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">HBV DNA </span><br> &lt;400 copies/mL (&lt;69 IU/mL)</td>
<td class="Rrule" align="center">
<br> 93%</td>
<td class="Rrule" align="center">
<br> 63%</td>
<td class="Rrule" align="center">
<br> 76%<br>
</td>
<td align="center">
<br> 13%</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">ALT </span><br> Normalized ALT<a name="footnote-reference-42" href="#footnote-42" class="Sup">†</a>
</td>
<td class="Rrule" align="center">76%</td>
<td class="Rrule" align="center">77%</td>
<td class="Rrule" align="center">68%</td>
<td align="center">54%</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">
<span class="Bold">Serology </span><br> HBeAg Loss/Seroconversion</td>
<td class="Rrule" align="center">
<br> NA<a name="footnote-reference-43" href="#footnote-43" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">
<br> NA<a href="#footnote-43" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">
<br> 20%/19%</td>
<td align="center">
<br> 16%/16%</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">HBsAg Loss/Seroconversion </td>
<td class="Rrule" align="center">0/0</td>
<td class="Rrule" align="center">0/0</td>
<td class="Rrule" align="center">3%/1%</td>
<td align="center">0/0</td>
</tr>
</tbody>
</table>
<p>A small proportion of nucleoside-experienced patients received VIREAD in the clinical trials: 43 patients in Study 0102 and 8 patients in Study 0103.  Across both studies, 5 patients had HBV containing lamivudine-resistance associated substitutions at baseline.  The numbers of patients in these subgroups were too small to establish efficacy.  </p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">The almond-shaped, light blue, film-coated tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil, are debossed with "GILEAD" and "4331" on one side and with "300" on the other side, and are available in unit of use bottles (containing a desiccant [silica gel canister or sachet] and closed with a child-resistant closure) of:</p>
<p>They are supplied by <span class="Bold"> State of Florida DOH Central Pharmacy</span> as follows:</p>
<table width="100%">
<colgroup>
<col width="13%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="12%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<td align="center"><span class="Bold">NDC</span></td>
<td align="center"><span class="Bold">Strength</span></td>
<td align="center"><span class="Bold">Quantity/Form</span></td>
<td align="center"><span class="Bold">Color</span></td>
<td align="center"><span class="Bold">Source Prod. Code</span></td>
</tr></thead>
<tbody><tr class="First Last">
<td align="center">53808-0810-1</td>
<td align="center">300 mg</td>
<td align="center">30 Tablets in a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</td>
<td align="center">Light Blue</td>
<td align="center">61958-0401</td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<h2></h2>
<p class="First">Store at 25 °C (77 °F), excursions permitted to 15–30 °C (59–86 °F) (see USP Controlled Room Temperature).</p>
<p><span class="Bold">Do not use if seal over bottle opening is broken or missing.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See <a href="#S17.2">FDA-approved patient labeling (17.2)</a></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Information for Patients</h2>
<p class="First">Patients should be advised that:</p>
<ul>
<li>VIREAD is not a cure for HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and patients may continue to experience illnesses associated with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, including <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>. Patients should remain under the care of a physician when using VIREAD.</li>
<li>The use of VIREAD has not been shown to reduce the risk of transmission of HIV-1 or HBV to others through sexual contact or blood contamination.</li>
<li>The long term effects of VIREAD are unknown.</li>
<li>VIREAD Tablets are for oral ingestion only.</li>
<li>VIREAD should not be discontinued without first informing their physician.</li>
<li>If you have HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, with or without HBV coinfection, it is important to take VIREAD with combination therapy.</li>
<li>It is important to take VIREAD on a regular dosing schedule and to avoid missing doses.</li>
<li><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported. Treatment with VIREAD should be suspended in any patient who develops clinical symptoms suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, unusual or unexpected <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>) <span class="Italics">[See <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</li>
<li>Patients with HIV-1 should be tested for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B virus (HBV) before initiating antiretroviral therapy <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
<li>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported in patients who are infected with HBV or coinfected with HBV and HIV-1 and have discontinued VIREAD <span class="Italics">[See <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</li>
<li>In patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, it is important to obtain HIV antibody testing prior to initiating VIREAD <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>].</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>, including cases of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4229557" conceptname="Fanconi syndrome">Fanconi syndrome</span>, has been reported. VIREAD should be avoided with concurrent or recent use of a nephrotoxic agent <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. Dosing interval of VIREAD may need adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a>]</span>.</li>
<li>VIREAD should not be coadministered with the fixed-dose combination products TRUVADA and ATRIPLA since it is a component of these products <span class="Italics">[See <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>VIREAD should not be administered in combination with HEPSERA <span class="Italics">[See <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</li>
<li>Decreases in bone mineral density have been observed with the use of VIREAD in patients with HIV.  Bone mineral density monitoring should be considered in patients who have a history of pathologic bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> or at risk for <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span> <span class="Italics">[See <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</li>
<li>In the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B, the optimal duration of treatment is unknown.  The relationship between response and long-term prevention of outcomes such as hepatocellular carcinoma is not known.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2	FDA-Approved Patient Labeling</h2>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">VIREAD<span class="Sup">® </span>(VEER ee ad) Tablets</span></p>
<p>Generic Name: tenofovir disoproxil fumarate (te NOE' fo veer dye soe PROX il FYOU-mar-ate)</p>
<p>Read this leaflet carefully before you start taking VIREAD. Also, read it each time you get your VIREAD prescription refilled, in case something has changed. This information does not take the place of talking with your healthcare provider when you start this medicine and at check ups. You should stay under a healthcare provider's care when taking VIREAD. Do not change or stop your medicine without first talking with your healthcare provider. Talk to your healthcare provider if you have any questions about VIREAD.</p>
<p><span class="Bold">What is VIREAD and how does it work?</span></p>
<p>VIREAD is a type of medicine called a nucleotide analog reverse transcriptase and HBV polymerase inhibitor (NRTI).  </p>
<p><span class="Italics">Use in the Treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>:</span></p>
<p>VIREAD is a treatment for Human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">Immunodeficiency</span> Virus (HIV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults age 18 years and older. VIREAD is always used in combination with other anti-HIV-1 medicines to treat people with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  </p>
<p><span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> destroys CD4<span class="Sup">+</span> T cells, which are important to the immune system. After a large number of T cells are destroyed, <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span> (AIDS) develops.</p>
<p>VIREAD helps to block HIV-1 reverse transcriptase, a chemical in your body (enzyme) that is needed for HIV-1 to multiply. VIREAD lowers the amount of HIV-1 in the blood (called viral load) and may help to increase the number of T cells (called CD4<span class="Sup">+</span> cells). Lowering the amount of HIV-1 in the blood lowers the chance of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that happen when your immune system is weak (<span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span>).</p>
<p><span class="Italics">Use in the Treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">Chronic Hepatitis</span> B:</span></p>
<p>VIREAD is also used to treat <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B (an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus [HBV]) in adults age 18 years and older.  VIREAD works by interfering with the normal working of an enzyme (HBV DNA polymerase) that is essential for the HBV virus to reproduce itself. VIREAD may help lower the amount of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus in your body by lowering the ability of the virus to multiply and infect new liver cells. </p>
<p><span class="Bold">Does VIREAD cure HIV-1 or AIDS?</span></p>
<p>VIREAD does not cure HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or AIDS. The long-term effects of VIREAD are not known at this time. People taking VIREAD may still get <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> or other conditions that happen with HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that develop because the immune system is weak. Some of these conditions are <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span>, and <span class="Italics">Mycobacterium avium </span>complex (MAC) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>We do not know how long VIREAD may help your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>.  Sometimes viruses change in your body and medicines no longer work.  This is called <span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">drug resistance</span>.</p>
<p>We do not know if VIREAD will reduce your chances of getting liver cancer from <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B.</p>
<p><span class="Bold">Does VIREAD reduce the risk of passing HIV-1 or HBV to others?</span></p>
<p>VIREAD does not reduce the risk of passing HIV-1 or HBV to others through sexual contact or blood contamination. Continue to practice safe sex and do not use or share dirty needles.</p>
<p><span class="Bold">Who should not take VIREAD?</span></p>
<p>Together with your healthcare provider, you need to decide whether VIREAD is right for you.</p>
<p>Do not take VIREAD if</p>
<ul>
<li>you are allergic to VIREAD or any of its ingredients</li>
<li>you are already taking TRUVADA<span class="Sup">®</span> or ATRIPLA<span class="Sup">®</span> because VIREAD  is one of the active ingredients in TRUVADA and ATRIPLA</li>
<li>you have not already discontinued treatment with HEPSERA<span class="Sup">®</span>
</li>
</ul>
<p><a name="doc"></a><span class="Bold">What should I tell my healthcare provider before taking VIREAD?</span></p>
<p><span class="Italics">Tell your healthcare provider</span></p>
<ul>
<li>
<span class="Italics">If you are pregnant or planning to become pregnant: </span>The effects of VIREAD on pregnant women or their unborn babies are not known.</li>
<li>
<span class="Italics">If you are breast-feeding:</span> Do not breast-feed if you are taking VIREAD. Do not breast-feed if you have HIV. If you are a woman who has or will have a baby, talk with your healthcare provider about the best way to feed your baby. If your baby does not already have HIV, there is a chance that the baby can get HIV through breast-feeding.</li>
<li><span class="Bold">If you have kidney or bone problems</span></li>
<li><span class="Bold">If you have liver problems including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B Virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></li>
<li><span class="Bold">If you have HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></li>
<li><span class="Bold">Tell your healthcare provider about all your medical conditions</span></li>
</ul>
<p><span class="Bold">TELL YOUR HEALTHCARE PROVIDER ABOUT ALL THE MEDICINES YOU TAKE</span>, INCLUDING PRESCRIPTION AND NON-PRESCRIPTION MEDICINES AND DIETARY SUPPLEMENTS. ESPECIALLY TELL YOUR HEALTHCARE PROVIDER IF YOU TAKE:</p>
<ul>
<li>VIDEX, VIDEX EC (DIDANOSINE). VIREAD MAY INCREASE THE AMOUNT OF VIDEX IN YOUR BLOOD. YOU MAY NEED TO BE FOLLOWED MORE CAREFULLY IF YOU ARE TAKING VIDEX AND VIREAD TOGETHER. IF YOU ARE TAKING VIDEX AND VIREAD TOGETHER YOUR HEALTHCARE PROVIDER MAY NEED TO REDUCE YOUR DOSE OF VIDEX.</li>
<li>REYATAZ (ATAZANAVIR SULFATE) OR KALETRA (LOPINAVIR/RITONAVIR). THESE MEDICINES MAY INCREASE THE AMOUNT OF VIREAD IN YOUR BLOOD, WHICH COULD RESULT IN MORE SIDE EFFECTS. YOU MAY NEED TO BE FOLLOWED MORE CAREFULLY IF YOU ARE TAKING VIREAD AND REYATAZ OR KALETRA TOGETHER. VIREAD MAY DECREASE THE AMOUNT OF REYATAZ IN YOUR BLOOD.  IF YOU ARE TAKING VIREAD AND REYATAZ TOGETHER YOU SHOULD ALSO BE TAKING NORVIR (RITONAVIR). </li>
</ul>
<p>IT IS A GOOD IDEA TO KEEP A COMPLETE LIST OF ALL THE MEDICINES THAT YOU TAKE. MAKE A NEW LIST WHEN MEDICINES ARE ADDED OR STOPPED.  GIVE COPIES OF THIS LIST TO ALL OF YOUR HEALTHCARE PROVIDERS <span class="Bold">EVERY</span> TIME YOU VISIT YOUR HEALTHCARE PROVIDER OR FILL A PRESCRIPTION.</p>
<p><span class="Bold">How should I take VIREAD?</span></p>
<ul>
<li>Stay under a healthcare provider's care when taking VIREAD. Do not change your treatment or stop treatment without first talking with your healthcare provider.</li>
<li>Take VIREAD exactly as your healthcare provider prescribed it. Follow the directions from your healthcare provider, exactly as written on the label. Set up a dosing schedule and follow it carefully.</li>
<li>If you are taking VIREAD to treat your HIV or if you have HIV and HBV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and are taking VIREAD, always take VIREAD in combination with other anti-HIV medicines. VIREAD and other products like VIREAD may be less likely to work in the future if you are not taking VIREAD with other anti-HIV medicines because you may develop resistance to those medicines. </li>
<li>Talk to your doctor about taking an HIV test before you start treatment with VIREAD for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B. </li>
<li>The usual dose of VIREAD is 1 tablet once a day.  If you have kidney problems, your healthcare provider may recommend that you take VIREAD less frequently.</li>
<li>VIREAD may be taken with or without a meal.</li>
<li>When your VIREAD supply starts to run low, get more from your healthcare provider or pharmacy. This is very important because the amount of virus in your blood may increase if the medicine is stopped for even a short time. The virus may develop resistance to VIREAD and become harder to treat.</li>
<li>Only take medicine that has been prescribed specifically for you. Do not give VIREAD to others or take medicine prescribed for someone else.</li>
</ul>
<p><span class="Bold">What should I do if I miss a dose of VIREAD?</span></p>
<p>It is important that you do not miss any doses. If you miss a dose of VIREAD, take it as soon as possible and then take your next scheduled dose at its regular time. If it is almost time for your next dose, do not take the missed dose. Wait and take the next dose at the regular time. Do not double the next dose.</p>
<p><span class="Bold">What happens if I take too much VIREAD?</span></p>
<p><span class="Bold">If you suspect that you took more than the prescribed dose of VIREAD, contact your local poison control center or emergency room right away.</span></p>
<p>As with all medicines, VIREAD should be kept out of reach of children.</p>
<p><span class="Bold">What should I avoid while taking VIREAD?</span></p>
<ul><li>Do not breast-feed. See "<a href="#doc">What should I tell my healthcare provider before taking VIREAD</a>?"</li></ul>
<p><span class="Bold">What are the possible side effects of VIREAD?</span></p>
<ul>
<li>Clinical studies in patients with HIV-1:  The most common side effects of VIREAD are: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.  Less common side effects include <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and intestinal gas.<br>Clinical studies in patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B:  The most common side effect of VIREAD is <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.  Less common side effects include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.</li>
<li>Marketing experience:  Other side effects reported since VIREAD has been marketed include: <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>, kidney problems (including decline or failure of kidney function), <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the pancreas, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> of the liver, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, and high volume of urine and <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span> caused by kidney problems.  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Muscle pain</span> and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span>, and softening of the bone (which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) as a consequence of kidney problems have been reported.</li>
<li>Some patients treated with VIREAD have had kidney problems. If you have had kidney problems in the past or need to take another drug that can cause kidney problems, your healthcare provider may need to perform additional blood tests.  </li>
<li>Laboratory tests show changes in the bones of patients treated with VIREAD.  If you have had bone problems in the past, your healthcare provider may need to perform additional tests or may suggest additional medication. Additionally, <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> and softening of the bone (which may contribute to <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) may occur as a consequence of kidney problems.</li>
<li>Some patients taking antiviral drugs like VIREAD have developed a condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> (a buildup in the blood of lactic acid, the same substance that causes your muscles to burn during heavy exercise). Symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, unusual or unexpected <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. If you notice these symptoms or if your medical condition changes suddenly, call your healthcare provider right away.</li>
<li>Changes in body fat have been seen in some patients taking anti-HIV-1 medicine. These changes may include increased amount of fat in the upper back and neck ("<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>"), breast, and around the main part of your body (trunk). Loss of fat from the legs, arms and face may also happen. The cause and long term health effects of these conditions are not known at this time.</li>
<li>In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS), signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment is started.  It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that may have been present with no obvious symptoms.  If you notice any symptoms of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, please inform your doctor immediately.</li>
<li>If you have HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or HIV and HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> together, you may have a "flare-up" of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B, in which the disease suddenly returns in a worse way than before if you stop taking VIREAD.  Do not stop taking VIREAD without your doctor's advice.  After stopping VIREAD, tell your doctor immediately about any new, unusual, or worsening symptoms that you notice after stopping treatment. After you stop taking VIREAD, your doctor will still need to check your health and take blood tests to check your liver for several months.</li>
<li>There have been other side effects in patients taking VIREAD. However, these side effects may have been due to other medicines that patients were taking or to the illness itself. Some of these side effects can be serious.</li>
<li>This list of side effects is <span class="Bold">not</span> complete. If you have questions about side effects, ask your healthcare provider. You should report any new or continuing symptoms to your healthcare provider right away. Your healthcare provider may be able to help you manage these side effects.</li>
</ul>
<p><span class="Bold">How do I store VIREAD?</span></p>
<ul>
<li>Keep VIREAD and all other medications out of reach of children.</li>
<li>Store VIREAD at room temperature 77 °F (25 °C). It should remain stable until the expiration date printed on the label.</li>
<li>Do not keep your medicine in places that are too hot or <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>.</li>
<li>Do not keep medicine that is out of date or that you no longer need. If you throw any medicines away make sure that children will not find them.</li>
</ul>
<p><span class="Bold">General advice about prescription medicines:</span></p>
<p>TALK TO YOUR HEALTHCARE PROVIDER IF YOU HAVE ANY QUESTIONS ABOUT THIS MEDICINE OR YOUR CONDITION. MEDICINES ARE SOMETIMES PRESCRIBED FOR PURPOSES OTHER THAN THOSE LISTED IN A PATIENT INFORMATION LEAFLET. IF YOU HAVE ANY CONCERNS ABOUT THIS MEDICINE, ASK YOUR HEALTHCARE PROVIDER. YOUR HEALTHCARE PROVIDER OR PHARMACIST CAN GIVE YOU INFORMATION ABOUT THIS MEDICINE THAT WAS WRITTEN FOR HEALTH CARE PROFESSIONALS. DO NOT USE THIS MEDICINE FOR A CONDITION FOR WHICH IT WAS NOT PRESCRIBED. DO NOT SHARE THIS MEDICINE WITH OTHER PEOPLE. </p>
<p>DO NOT USE IF SEAL OVER BOTTLE OPENING IS BROKEN OR MISSING.</p>
<p><span class="Bold">What are the ingredients of VIREAD?</span></p>
<p>Active Ingredient:  tenofovir disoproxil fumarate</p>
<p>Inactive Ingredients:  croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The tablets are coated with Opadry II Y–30–10671–A, which contains FD&amp;C blue #2 aluminum lake, hydroxypropyl methylcellulose 2910, lactose monohydrate, titanium dioxide, and triacetin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First">VIREAD, EMTRIVA, HEPSERA  and TRUVADA are registered trademarks of Gilead Sciences, Inc. ATRIPLA is a trademark of Bristol-Myers Squibb &amp; Gilead Sciences, LLC. All other trademarks referenced herein are the property of their respective owners.</p>
<p>This Product was Repackaged By:</p>
<p><span class="Bold">State of Florida DOH Central Pharmacy</span><br>
104-2 Hamilton Park Drive<br>
Tallahassee, FL 32304<br>
United States<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack Label</span></p>
<p>NDC 53808-0810-1</p>
<p><span class="Bold">Viread<span class="Sup">®</span><br>(tenofovir disoproxil<br>fumarate) Tablets, 300 mg</span></p>
<p><span class="Bold">30 tablets</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Label Image for 300mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e122435e-cd0b-4c90-940a-b7a0d090d866&amp;name=Viread%20300mg%20(Gilead).jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VIREAD 		
					</strong><br><span class="contentTableReg">tenofovir disoproxil fumarate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:53808-0810(NDC:61958-0401)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TENOFOVIR DISOPROXIL FUMARATE</strong> (tenofovir) </td>
<td class="formItem">tenofovir</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light Blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">FREEFORM (almond-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">17mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GILEAD;4331;300</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:53808-0810-1</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021356</td>
<td class="formItem">07/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>State of Florida DOH Central Pharmacy
							(829348114)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">State of Florida DOH Central Pharmacy</td>
<td class="formItem"></td>
<td class="formItem">829348114</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bea0f43d-4f45-40d2-b4a4-3ac996bb1626</div>
<div>Set id: e122435e-cd0b-4c90-940a-b7a0d090d866</div>
<div>Version: 1</div>
<div>Effective Time: 20100413</div>
</div>
</div> <div class="DistributorName">State of Florida DOH Central Pharmacy</div></p>
</body></html>
